[0034] Winkler R, Gillis E, Lasman L, Safra M, Geula S, Soyris C, Nachshon A, Tai-Schmiedel J, Friedman N, Le-Trilling Vu T K, Trilling M, Mandelboim M, Hanna, J H, Schwartz S, Stern-Ginossar N. Nature Immunology (2018, e-publication ahead of print).

[0035] Yue Y, Liu J, He C. Genes Dev. 2015 Jul 1;29(13):1343-55.

[0036] Geon-Woo Kim, Hasan Imam, Mohsin Khan, Aleem Siddiqui, J Biol Chem, (27 Jul 2020; online publication ahead of print).

[0037] Yimeng Gao, Radovan Vasic, Yuanbin Song, Rhea Teng, Chengyang Liu , Rana Gbyli, Giulia Biancon, Raman Nelakanti, Kirsten Lobben, Eriko Kudo, Wei Liu, Anastasia Ardasheva, Xiaoying Fu, Xiaman Wang, Poorval Joshi, Veronica Lee, Burak Dura, Gabriella Viero, Akiko Iwasaki, Rong Fan, Andrew Xiao, Richard A Flavell, Hua-Bing Li, Toma Tebaldi, Stephanie Halene; Immunity (16 June 2020; Volume 52; 6; p887-1132).

[0038] Rosa M Rubio, Daniel P Depledge, Christopher Bianco, Letitia Thompson, Ian Mohr; Genes Dev. 2018 Dec 1;32(23-24):1472-1484.

[0039] An object of this invention is to provide inhibitors of METTL3 activity.

SUMMARY ~~OF THE INVENTION~~


[0039a] In a first aspect, the present disclosure refers to a compound of formula (I) shown below, or a pharmaceutically acceptable salt thereof:

X – Y – Z


(I)

wherein:


X is selected from:




;




;




;



;





; and

wherein

Q_1 is selected from NH, N-C_{1-4}alkyl, O or S;

Q_{2a} is selected from N or CR_{2a};

Q_{2b} is selected from N or CR_{2b};

Q_{2c} is selected from N or CR_{2c};

Q_{2d} is selected from N or CR_{2d};

Q_3 is selected from N or CR_{1b};

Q_4 is selected from N or CR_{1x};

subject to the proviso that no more than 3 of Q_1, Q_{2a}, Q_{2b}, Q_{2c}, Q_{2d}, Q_3 and Q_4 are nitrogen;

R_{1a} is selected from:

(i) C_{1-4}alkyl or C_{1-4}alkoxy, each of which being optionally subsutited by halo, cyano, hydroxy, C_{3-6}cycloalkyl, a 3 to 6 membered heterocyclyl C_{1-4}alkoxy, C_{1-4}haloalkoxy, aryl or heteroaryl; or

(ii) a group of the formula:

$$–(CR_{1c}R_{1d})_p–NR_{1e}R_{1f};$$

wherein

p is an integer selected from 0, 1, 2 or 3

R_{1c} and R_{1d} are independently selected from:

(i) hydrogen (including deuterium),

(ii) C_{1-6}alkyl which is optionally substituted by one more substituents selected from cyano, oxo, hydroxy, C_{1-4}alkoxy, halo, C_{1-4}haloalkoxy, C_{3-6}cycloalkyl, -O-C_{3-6}cycloalkyl, $NR_{1ca}R_{1da}$ or -$S(O)_{0-2}R_{1ca}R_{1da}$, wherein R_{1ca} and R_{1da} are H or C_{1-2}alkyl; and wherein C_{3-6}cycloalkyl and -O-C_{3-6}cycloalkyl are optionally further subsitutued with halo, cyano or hydroxy;

(iii) C_{3-4}cycloalkyl or 3 to 5 membered heterocyclyl, each of which is optionally substituted by C_{1-4}alkyl, C_{1-4}haloalkyl, cyano, hydroxy, C_{1-2}alkoxy, halo, C_{1-2}haloalkoxy, $NR_{1ca}R_{1da}$ or $-S(O)_{0-2}R_{1ca}R_{1da}$, wherein R_{1ca} and R_{1da} are H or C_{1-2}alkyl;

(iv) or R_{1c} and R_{1d} are linked together such that, together with the carbon atom to which they are attached, they form a 3- to 6-membered cycloalkyl or heterocyclic ring, or a spirocyclic ring system, each of which is optionally substituted by one or more substituents selected from C_{1-2}alkyl, C_{1-2}haloalkyl, cyano, hydroxy, C_{1-2}alkoxy, halo, C_{1-2}haloalkoxy, $NR_{1ca}R_{1da}$ or $-S(O)_{0-2}R_{1ca}R_{1da}$, wherein R_{1ca} and R_{1da} are H or C_{1-2}alkyl;

R_{1e} and R_{1f} are each independently selected from:

(i) hydrogen (including deuterium);

(ii) C_{1-6}alkyl which is optionally substituted by one more substituents selected from cyano, oxo, hydroxy, C_{1-2}alkoxy, halo, C_{1-2}haloalkoxy, $NR_{1ea}R_{1fa}$ or $-S(O)_{0-2}R_{1ea}R_{1fa}$, wherein R_{1ea} and R_{1fa} are H or C_{1-2}alkyl;

(iii) a group with the formula:

$$-(CR_{1g}R_{1h})_q-T_1$$

wherein:

q is 0, 1, 2, 3, 4, 5 or 6;

R_{1g} and R_{1h} are independently selected from:

a) hydrogen;

b) C_{1-6}alkyl which is optionally substituted by one more substituents selected from cyano, hydroxy, C_{1-4}alkoxy, halo, C_{1-4}haloalkoxy, -O-C_{3-6}cycloalkyl, $NR_{1ga}R_{1ha}$ or $-S(O)_{0-2}R_{1ga}R_{1ha}$, wherein R_{1ga} and R_{1ha} are H or C_{1-2}alkyl; and wherein -O-C_{3-6}cycloalkyl is optionally subsitutued with halo, cyano or hydroxy;

c) an aryl-C_{1-6}alkyl, heteroarylC_{1-6}alkyl, C_{3-6}cycloalkyl or C_{3-6}-cycloalkylC_{1-6}alkyl group, each of which is optionally substituted by one or more substituents selected from C_{1-2}-alkyl, cyano, C_{1-2}haloalkyl, hydroxy, C_{1-2}alkoxy, halo, C_{1-2}-haloalkoxy, $NR_{1ga}R_{1ha}$ or $-S(O)_{0-2}R_{1ga}R_{1ha}$, wherein R_{1ga} and R_{1ha} are H or C_{1-2}alkyl; or

d) R_{1g} and R_{1h} are optionally linked together such that, together with the carbon atom to which they are attached, they form a 3- to 6-membered cycloalkyl or heterocyclic ring which is optionally substituted by one or more substituents selected from C_{1-2}alkyl, cyano, C_{1-2}haloalkyl, hydroxy, C_{1-2}alkoxy, halo, C_{1-2}haloalkoxy, $NR_{1ga}R_{1ha}$ or $-S(O)_{0-2}R_{1ga}R_{1ha}$, wherein R_{1ga} and R_{1ha} are H or C_{1-2}alkyl; and

T_1 is selected from hydrogen, halo, C_{1-4}alkyl, C_{1-4}haloalkyl, cyano, hydroxy, $NR_{1t}R_{2t}$ or $-S(O)_{0-2}R_{1t}R_{2t}$ (wherein R_{1t} and R_{2t} are H or C_{1-4}alkyl), C_{3-8}cycloalkyl, C_{2-3}alkenyl, C_{2-3}alkynyl, aryl, heterocyclyl, a mono- or bicyclic heteroaryl, a spirocyclic carbocyclic or heterocyclic ring system, a bridged C_{3-8}cycloalkyl, a bridged bicyclic C_{5-12}cycloalkyl, or a bridged heterocyclic ring system, each of which is optionally substituted by one or more substituents selected from C_{1-2}alkyl, C_{1-2}haloalkyl, cyano, hydroxy, C_{1-2}alkoxy, halo, C_{1-2}-haloalkoxy, C_{3-6}cycloalkyl, $NR_{3t}R_{4t}$ or $-S(O)_{0-2}R_{3t}R_{4t}$, wherein R_{3t} and R_{4t} are H or C_{1-2}alkyl;

(iv) or R_{1e} and R_{1f} are linked such that, together with the nitrogen atom to which they are attached, they form a mono- or bicyclic-heterocyclic ring, which is optionally substituted by one or more substituents selected from C_{1-4}alkyl, C_{1-4}haloalkyl, C_{3-6}cycloalkyl, cyano, hydroxy, C_{1-4}alkoxy, halo, C_{1-4}haloalkoxy, $NR_{1i}R_{1j}$ or $-S(O)_{0-2}R_{1i}R_{1j}$, wherein R_{1i} and R_{1j} are H or C_{1-4}alkyl, and/or the mono- or bicyclic hetereocyclic ring formed by R_{1e} and R_{1f} is optionally spiro-fused to a C_{3-6}cycloalkyl or a heterocyclic ring, which in turn is optionally substituted by one or more substituents selected from C_{1-4}alkyl, C_{1-4}haloalkyl, C_{3-6}cycloalkyl, cyano, hydroxy, C_{1-4}alkoxy, halo, C_{1-4}haloalkoxy, $NR_{1i}R_{1j}$ or $-S(O)_{0-2}R_{1i}R_{1j}$, wherein R_{1i} and R_{1j} are H or C_{1-4}alkyl; wherein any wherein any alkyl, alkoxy or C_{3-6}cycloalkyl is further optionally substituted by one or more substituents selected from cyano, hydroxy, halo, $NR_{1k}R_{1l}$ or $-S(O)_{0-2}R_{1k}R_{1l}$, wherein R_{1k} and R_{1l} are H or C_{1-4}alkyl

R_{1b} is selected from hydrogen, cyano, halo or C_{1-3} alkyl;

R_{1x} is selected from hydrogen, cyano, halo or C_{1-3} alkyl;

R_{2a}, R_{2b}, R_{2c} and R_{2d} are independently selected from hydrogen, cyano, halo or a group of the formula:

$$-L_{2a}-L_{2b}-Q_2$$


wherein


L_{2a} is absent or C_{1-3}alkylene optionally substituted by C_{1-2} alkyl or oxo;


L_{2b} is absent or selected from O, S, SO, SO_2, $N(R_n)$, C(O), C(O)O, OC(O), $C(O)N(R_n)$, $N(R_n)C(O)$, $N(R_n)C(O)N(R_o)$, $S(O)_2N(R_n)$, or $N(R_n)SO_2$, wherein R_n and R_o are each independently selected from hydrogen or C_{1-2}alkyl; and


Q_2 is hydrogen, cyano, C_{1-6}alkyl, C_{3-6}cycloalkyl, aryl, heterocyclyl or heteroaryl, each of which is optionally substituted by one or more substituents selected from halo, trifluoromethyl, trifluoromethoxy, amino, cyano, hydroxy, amino, carboxy, carbamoyl, sulphamoyl, C_{1-4}alkyl, NR_pR_g, OR_p, $C(O)R_p$, $C(O)OR_p$, $OC(O)R_p$, $C(O)N(R_p)R_g$, $N(R_r)C(O)R_p$, $S(O)_yR_p$ (where y is 0, 1 or 2), $SO_2N(R_p)R_g$, $N(R_r)SO_2R_p$ or $(CH_2)_zNR_pR_g$ (where z is 1, 2 or 3), wherein R_p and R_g are each independently selected from hydrogen or C_{1-4}alkyl;


Y is selected from:

















,




,




,




,







and




;



,





and ;

wherein:

R_{3a1}, R_{3b1}, R_{3c1}, R_{3d1}, R_{3e1}, R_{3f1}, R_{3g1}, R_{3h1}, R_{3i1}, R_{3j1}, R_{3k1}, R_{3l1}, R_{3m1}, R_{3n1}, R_{3o1}, R_{3p1},R_{3q1}, R_{3r1} and R_{3s1} are independently selected from hydrogen (including deuterium), $C_{1\text{-}6}$alkyl, $C_{3\text{-}4}$ cycloalkyl, hydroxy, and halo; and wherein $C_{1\text{-}6}$alkyl, or $C_{3\text{-}4}$ cycloalkyl is optionally substituted with one or more substituents selected from halo, amino, cyano, and hydroxy;


R_{3a2}, R_{3b2}, R_{3c2}, R_{3d2}, R_{3e2}, R_{3f2}, R_{3g2}, R_{3h2}, R_{3i2}, R_{3j2}, R_{3k2}, R_{3l2}, R_{3m2}, R_{3n2}, R_{3o2}, R_{3p2}-, R_{3q2}, R_{3r2} and R_{3s2} are hydrogen or halo;


with the proviso that R_{3a1}, R_{3b1}, R_{3i1}, R_{3l1}, R_{3o1}, R_{3r1}, R_{3a2}, R_{3b2}, R_{3i2}, R_{3l2}, R_{3o2} and R_{3s1} cannot be halo when n=1 or when n=2 and the carbon atom to which they are attached is linked to an oxygen or nitrogen atom;


or R_{3a1} and R_{3a2}, R_{3b1} and R_{3b2}, R_{3c1} and R_{3c2}, R_{3d1} and R_{3d2}, R_{3e1} and R_{3e2}, R_{3f1} and R_{3f2}, R_{3g1} and R_{3g2}, R_{3h1} and R_{3h2}, R_{3i1} and R_{3i2}, R_{3j1} and R_{3j2}, R_{3k1} and R_{3k2}, R_{3l1} and R_{3l2}, R_{3m1} and R_{3m2}, R_{3n1} and R_{3n2}, R_{3o1} and R_{3o2}, R_{3p1} and R_{3p2}, R_{3q1} and R_{3q2}, or R_{3r1} and R_{3r2} or R_{3s1} and R_{3s2} may be linked such that, together with the carbon atom to which they are attached, they form a spiro-fused C_{3-4}cycloalkyl which is optionally substituted with one or more substituents selected from halo, methyl, amino, cyano, and hydroxy;


n is 0, 1 or 2


Z is selected from:





,







,



,






,



,


5g



A6
RZ1
A5
N
RZi1b
N
RZ2



A6
RZ1
N
NH
N
RZ2



A6
A5
N
NH
N
RZ2



A6
RZ1
A5
RZi1b
N
N
RZ2N


A6
RZ1
A5
N
RZi1b
N
N



A7
RZ1a
RZ3a
N
RY5N
N
RZ2a



A7
N
RZ3a
N
RY5N
RZ2a
RZi2e


A7
N
RZ3a
N
RY5N
N
RZi2e



A7
N
N
N
RY5N
RZ2a
RZi2e

5h







,




,




,




,



,





, and ,

wherein:

R_4 is selected from hydrogen, halo, cyano, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4}alkoxy, C_{1-4} haloalkoxy (e.g. hydrogen, halo, cyano and methyl);

R_5 is selected from hydrogen, halo, cyano, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4}alkoxy, C_{1-4} haloalkoxy (e.g. hydrogen, halo, cyano and methyl);

R_6 is selected from hydrogen, halo, cyano, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4}alkoxy, C_{1-4} haloalkoxy (e.g. hydrogen, halo, cyano and methyl);

R_8, R_9, R_{10} and R_{11} are independently selected from hydrogen, NH_2, halo, cyano, C_{1-4} alkoxy, C_{1-4} haloalkoxy, C_{1-6} alkyl, $-CH_2OCH_3$, $-CH_2SO_2CH_3$, $-SO_2CH_3$, $-NHC(O)CH_3$ and $-C(O)NR_{v1}R_{v2}$, wherein R_{v1} and R_{v2} are independently selected from hydrogen and methyl; or

R_9 and R_{10} may be linked together such that, together to the atoms to which they are attached, they form a fused 5- or 6-membered saturated or unsaturated ring system, or R_{10} and R_{11} may be linked together such that, together to the atoms to which they are attached, they form a fused 5- or 6-membered saturated or unsaturated ring system, wherein either of the fused 5- or 6-membered saturated or unsaturated ring system may be optionally subsitutued by one or more substituents selected from C_{1-2}alkyl, cyano, C_{1-2}haloalkyl, hydroxy, C_{1-2}alkoxy, halo, C_{1-2}haloalkoxy, $NR_{1ia}R_{1ja}$ or $-S(O)_{0-2}R_{1ia}R_{1ja}$, wherein R_{1ia} and R_{1ja} are H or C_{1-2}alky;

R_7 and R_{11N} are independently selected from hydrogen, NH_2, halo, cyano, and C_{1-6} alkyl;

R_{Z1} and R_{Z1a} selected from hydrogen, C_{1-4}alkyl, cyano, halo, C_{1-4}haloalkyl, C_{1-4}haloalkoxy, C_{1-4}alkoxy, C_{3-6}cycloalkyl and -O-C_{3-6}cycloalkyl, wherein C_{3-6}cycloalkyl and -O-C_{3-6}cycloalkyl are optionally subsitutued by one or more of halo, methyl or methoxy;

R_{Z2} and R_{Z2a} are selected from hydrogen, C_{1-4}alkyl, cyano, halo, NH_2 and C_{1-4}alkoxy;

R_{Z3a} is selected from hydrogen, C_{1-4}alkyl, cyano, halo, NH_2 and C_{1-4}alkoxy;

R_{Zi1b} is selected from hydrogen, C_{1-4}alkyl, cyano, halo, NH_2 and C_{1-4}alkoxy;

R_{Zi2e} is selected from hydrogen, C_{1-4}alkyl, cyano, halo, NH_2 and C_{1-4}alkoxy;

R_{Y5N} and R_{Z2N} are selected from hydrogen or C_{1-4}alkyl;

R_{Z9} is selected from hydrogen, halo, cyano, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4}alkoxy, C_{1-4} haloalkoxy;

R_{Z10} is selected from hydrogen, halo, cyano, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4}alkoxy, C_{1-4} haloalkoxy;

R_{Z11} is selected from hydrogen, halo, cyano, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4}alkoxy, C_{1-4} haloalkoxy;

R_{Z12} is selected from hydrogen, halo, cyano, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4}alkoxy, C_{1-4} haloalkoxy;

R_{Z13} is selected from hydrogen, halo, cyano, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4}alkoxy, C_{1-4} haloalkoxy;

R_{Z14} is selected from hydrogen, halo, cyano, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4}alkoxy, C_{1-4} haloalkoxy;

R_{Z15} is selected from hydrogen, halo, cyano, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4}alkoxy, C_{1-4} haloalkoxy;

R_{Z16} is selected from hydrogen, halo, cyano, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4}alkoxy, C_{1-4} haloalkoxy;

A_1 is selected from CR_{12} and N;

A_2 is selected from CR_{13} and N;

A_5 is selected from CR_{16} and N;

A_6 is selected from CR_{17} and N;

A_7 is selected from CR_{18} and N;

A_8 is selected from $CR_{19}R_{20}$ and NR_{21};

A_9 is selected from $CR_{22}R_{23}$ and NR_{24};

A_{11} is selected from $CR_{28}R_{29}$ and NR_{30};

R_{12} is selected from hydrogen, halo, cyano, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4}alkoxy, C_{1-4} haloalkoxy (e.g. hydrogen, halo, cyano and C_{1-4} alkyl);

R_{13} is selected from hydrogen, halo, cyano, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4}alkoxy, C_{1-4} haloalkoxy (e.g. hydrogen, halo, cyano, methoxy and methyl);

R_{16} and R_{18} are selected from hydrogen, halo, cyano, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4}haloalkyl, C_{1-4}haloalkoxy, C_{3-4}cycloalkyl, a 3- to 4-membered heterocyclyl and C_{3-4}-cycloalkoxy;

R_{17} is selected from hydrogen, halo, cyano, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} alkoxy, C_{1-4} haloalkoxy, C_{2-4} alkenyl, C_{2-4} alkynyl, phenyl, a 5- or 6-membered or heteroaryl, C_{3-6}cycloalkyl, -O-C_{3-6}cycloalkyl, heterocyclyl, -O-heterocyclyl (carbon-linked), -$(OCH_2CH_2)_m$-OCH_3 wherein m is an integer from 1 to 6, NR_gR_r, wherein R_g and R_r are each independently hydrogen, C_{1-5} alkyl, C_{3-6}cycloalkyl, a 3- to 6- membered carbon-linked heterocyclyl, or R_g and R_r are linked together such that, together with the nitrogen atom to which they are attached, they form a 3- to 6-membered heterocyclic ring; wherein any C_{1-5}alkyl, C_{1-4} alkoxy, C_{2-4}alkenyl, C_{2-4}alkynyl , phenyl, 5- or 6-membered or heteroaryl, C_{3-6}cycloalkyl, -O-C_{3-6}cycloalkyl, heterocyclyl or -O-heterocyclyl (carbon-linked)is optionally further substituted by one or more substituents selected from C_{1-2}alkyl, cyano, C_{1-2}haloalkyl, hydroxy, C_{1-2}alkoxy, halo, C_{1-2}haloalkoxy, $NR_{1ea}R_{1fa}$ or -$S(O)_{0-2}R_{1ea}R_{1fa}$, wherein R_{1ea} and R_{1fa} are H or C_{1-2}alkyl;

R_{19} and R_{20} are selected from hydrogen, halo, cyano and C_{1-4} alkyl;

R_{22} and R_{23} are selected from hydrogen, halo, cyano, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4}alkoxy, C_{1-4} haloalkoxy (e.g. hydrogen, halo, cyano and methyl;

R_{28} and R_{29} are selected from hydrogen, halo, methoxy and methyl;

R_{21}, R_{24} and R_{30} are hydrogen or C_{1-4}alkyl.

[0039b] In another aspect, the present disclosure refers to a compound, or a pharmaceutically acceptable salt thereof, selected from any one of the following:

N-({2-[(4,4-dimethylpiperidin-1-yl)methyl]-1H-indol-6-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[(cyclobutylmethyl)amino]methyl}-1H-indol-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[[(3,3-difluorocyclobutyl)methylamino]methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[[(1-hydroxycyclobutyl)methylamino]methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[[(1-fluorocyclobutyl)methylamino]methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[[(1-methylcyclopropyl)methylamino]methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide.

N-[[2-(2-azabicyclo[2.1.1]hexan-2-ylmethyl)-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-(3-azabicyclo[3.1.1]heptanean-3-ylmethyl)-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[[2-(hydroxymethyl)pyrrolidin-1-yl]methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-(morpholinomethyl)-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[(1-adamantylamino)methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

4-oxo-N-[[2-(1-piperidylmethyl)-1H-indol-6-yl]methyl]pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[(4-fluoro-1-piperidyl)methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

4-oxo-N-[[2-[[[rac-(1S,2S,4S)-7-oxabicyclo[2.2.1]heptane-5-en-2-yl]methylamino]methyl]-1H-indol-6-yl]methyl]pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[[(1-hydroxycyclopentyl)methylamino]methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

4-oxo-N-[[2-[[[rac-(1S,2R,4S)-7-oxabicyclo[2.2.1]heptane-5-en-2-yl]methylamino]methyl]-1H-indol-6-yl]methyl]pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[(1-bicyclo[1.1.1]pentanylamino)methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[(cyclobutylamino)methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-({2-[({bicyclo[2.2.1]heptanean-2-yl}amino)methyl]-1H-indol-6-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[(cyclopropylamino)methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-(2-azabicyclo[2.2.2]octan-2-ylmethyl)-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[[(2,2-difluorocyclopropyl)methylamino]methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[({3-fluorobicyclo[1.1.1]pentan-1-yl}methyl)amino]methyl}-1H-indol-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[(cyclohexylmethylamino)methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[[(1-hydroxycyclohexyl)methylamino]methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[(cyclopentylamino)methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[(cyclopentylmethylamino)methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[[(1-methoxycyclobutyl)methylamino]methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[(isobutylamino)methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[(cyclohexylamino)methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[(cyclopropylmethylamino)methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

4-oxo-N-[[2-[(prop-2-ynylamino)methyl]-1H-indol-6-yl]methyl]pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[(oxetan-2-ylmethylamino)methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[(2,2-dimethylpropylamino)methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[(1-bicyclo[1.1.1]pentanylmethylamino)methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-{[2-({[(1S,2S)-2-hydroxycyclopentyl]amino}methyl)-1H-indol-6-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

5m

N-{[2-({[(1R,2R)-2-hydroxycyclopentyl]amino}methyl)-1H-indol-6-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-{[2-({[(1S,2R)-2-hydroxycyclopentyl]amino}methyl)-1H-indol-6-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-{[2-({[(1R,2S)-2-hydroxycyclopentyl]amino}methyl)-1H-indol-6-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[(cyclopropylmethylamino)methyl]-5-fluoro-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[(cyclobutylmethylamino)methyl]-5-fluoro-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

4-oxo-N-[[2-[(2,2,2-trifluoroethylamino)methyl]-1H-indol-6-yl]methyl]pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[N-(cyclobutylmethyl)acetamido]methyl}-1H-indol-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

4-oxo-N-{[2-(piperidin-2-yl)-1H-indol-6-yl]methyl}-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[(cyclobutylmethyl)amino]methyl}-3-fluoro-1H-indol-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[(cyclobutylmethyl)amino]methyl}-1-methyl-1H-indol-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[(Cyclobutylmethylamino)-dideuterio-methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[(cyclobutylmethylamino)methyl]-1H-indol-6-yl]methyl]-1H-indazole-4-carboxamide

N-[[2-[(cyclobutylmethylamino)methyl]-1H-pyrrolo[3,2-b]pyridin-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-(1H-indol-6-ylmethyl)-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-(1H-indol-2-ylmethyl)-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-(indolizin-2-ylmethyl)-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(6-{[4-(1H-indazol-4-yl)-1H-1,2,3-triazol-1-yl]methyl}-1H-indol-2-yl)methyl]cyclopropanamine

(1R,2S)-2-[[6-[[4-(1H-indazol-4-yl)triazol-1-yl]methyl]-1H-indol-2-yl]methylamino]cyclopentanol

N-[[6-[[4-(1H-indazol-4-yl)triazol-1-yl]methyl]-1H-indol-2-yl]methyl]cyclopentanamine

N-(cyclopropylmethyl)-1-[6-[[4-(1H-indazol-4-yl)triazol-1-yl]methyl]-1H-indol-2-yl]methanamine

1-[[[6-[[4-(1H-indazol-4-yl)triazol-1-yl]methyl]-1H-indol-2-yl]methylamino]methyl]cyclobutanol

N-(cyclobutylmethyl)-1-[6-[[4-(1H-indazol-4-yl)triazol-1-yl]methyl]-1H-indol-2-yl]methanamine

5n

N-(cyclobutylmethyl)-1-[6-[[4-(1H-indazol-4-yl)triazol-1-yl]methyl]-1H-pyrrolo[3,2-b]pyridin-2-yl]methanamine

N-(cyclobutylmethyl)-1-[6-[[4-(1H-indazol-4-yl)triazol-1-yl]methyl]-1H-pyrrolo[3,2-c]pyridin-2-yl]methanamine

N-(cyclobutylmethyl)-1-[6-[[4-(1H-indazol-4-yl)triazol-1-yl]methyl]-1H-pyrrolo[3,2-c]pyridin-2-yl]methanamine

2-[1-[[2-[(cyclobutylmethylamino)methyl]-1H-indol-6-yl]methyl]triazol-4-yl]pyrido[1,2-a]pyrimidin-4-one

N-(cyclobutylmethyl)-1-[6-[[4-(6-methoxyimidazo[1,5-a]pyridin-8-yl)triazol-1-yl]methyl]-1H-indol-2-yl]methanamine

N-(cyclobutylmethyl)-1-[6-[[4-(1H-indazol-4-yl)imidazol-1-yl]methyl]-1H-indol-2-yl]methanamine

N-(cyclobutylmethyl)-1-[6-[[3-(1H-indazol-4-yl)-1,2,4-oxadiazol-5-yl]methyl]-1H-indol-2-yl]methanamine

N-[[2-(2-azaspiro[3.3]heptanean-2-ylmethyl)-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[(benzylamino)methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-(3-azabicyclo[3.1.0]hexan-3-ylmethyl)-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[[cyclobutylmethyl(methyl)amino]methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[(cyclobutylmethylamino)methyl]-1H-pyrrolo[2,3-b]pyridin-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[(cyclobutylmethyl)amino]methyl}-1H-1,3-benzodiazol-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[(but-2-yn-1-yl)amino]methyl}-1H-indol-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[(3-cyclopropylprop-2-yn-1-yl)amino]methyl}-1H-indol-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-({2-[({bicyclo[3.1.0]hexan-6-yl}amino)methyl]-1H-indol-6-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[({bicyclo[2.1.1]hexan-1-yl}methyl)amino]methyl}-1H-indol-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[({3-methylbicyclo[1.1.1]pentan-1-yl}methyl)amino]methyl}-1H-indol-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-({2-[(3-methylazetidin-1-yl)methyl]-1H-indol-6-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-({2-[(3-fluoroazetidin-1-yl)methyl]-1H-indol-6-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-({2-[(azetidin-1-yl)methyl]-1H-indol-6-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-{[2-({2-azaspiro[3.4]octan-2-yl}methyl)-1H-indol-6-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-({2-[(3-hydroxyazetidin-1-yl)methyl]-1H-indol-6-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-({2-[(3,3-dimethylazetidin-1-yl)methyl]-1H-indol-6-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

4-oxo-N-[(2-{[3-(2,2,2-trifluoroethoxy)azetidin-1-yl]methyl}-1H-indol-6-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[3-(difluoromethyl)azetidin-1-yl]methyl}-1H-indol-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-({2-[(3-methoxyazetidin-1-yl)methyl]-1H-indol-6-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[3-(tert-butoxy)azetidin-1-yl]methyl}-1H-indol-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

4-oxo-N-[(2-{[3-(trifluoromethyl)azetidin-1-yl]methyl}-1H-indol-6-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-({2-[(3-ethoxyazetidin-1-yl)methyl]-1H-indol-6-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-{[2-({2-azaspiro[3.5]nonan-2-yl}methyl)-1H-indol-6-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-({2-[(2-methylazetidin-1-yl)methyl]-1H-indol-6-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-({2-[(3,3-dimethylpyrrolidin-1-yl)methyl]-1H-indol-6-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-{[2-({6-fluoro-2-azaspiro[3.3]heptanean-2-yl}methyl)-1H-indol-6-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-{[2-({6,6-difluoro-2-azaspiro[3.3]heptanean-2-yl}methyl)-1H-indol-6-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-({2-[(3-cyclobutylazetidin-1-yl)methyl]-1H-indol-6-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-({2-[(3-cyclopropylazetidin-1-yl)methyl]-1H-indol-6-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-({2-[(3-tert-butylazetidin-1-yl)methyl]-1H-indol-6-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[(1-tert-butylcyclopropyl)amino]methyl}-1H-indol-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-{[2-({[(3-methylcyclobutyl)methyl]amino}methyl)-1H-indol-6-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

4-oxo-N-[(2-{[(2,3,3-trimethylbutan-2-yl)amino]methyl}-1H-indol-6-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[({imidazo[1,2-a]pyridin-2-yl}methyl)amino]methyl}-1H-indol-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-({2-[(3,3-diethylazetidin-1-yl)methyl]-1H-indol-6-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

4-oxo-N-[(2-{[(pent-3-yn-1-yl)amino]methyl}-1H-indol-6-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-{[2-({6-azaspiro[3.4]octan-6-yl}methyl)-1H-indol-6-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-({2-[(2,2-dimethylpyrrolidin-1-yl)methyl]-1H-indol-6-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-{[2-({octahydrocyclopenta[c]pyrrol-2-yl}methyl)-1H-indol-6-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-{[2-({5-azaspiro[2.4]heptanean-5-yl}methyl)-1H-indol-6-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[({3-methoxybicyclo[1.1.1]pentan-1-yl}methyl)amino]methyl}-1H-indol-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

4-oxo-N-[(2-{[({spiro[2.2]pentan-1-yl}methyl)amino]methyl}-1H-indol-6-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

4-oxo-N-({2-[({spiro[2.3]hexan-1-yl}amino)methyl]-1H-indol-6-yl}methyl)-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[({3-cyanobicyclo[1.1.1]pentan-1-yl}methyl)amino]methyl}-1H-indol-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-{[2-({1-oxa-6-azaspiro[3.4]octan-6-yl}methyl)-1H-indol-6-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-{[2-({2-azaspiro[4.4]nonan-2-yl}methyl)-1H-indol-6-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[(1-methylcyclopentyl)amino]methyl}-1H-indol-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-{[2-(hydroxymethyl)-1H-indol-6-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[(1-cyclobutylcyclopropyl)amino]methyl}-1H-indol-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-{[2-({[(1-methylcyclobutyl)methyl]amino}methyl)-1H-indol-6-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

4-oxo-N-[(2-{[({spiro[2.3]hexan-5-yl}methyl)amino]methyl}-1H-indol-6-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-({2-[({[3-(fluoromethyl)bicyclo[1.1.1]pentan-1-yl]methyl}amino)methyl]-1H-indol-6-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[(1-{3-fluorobicyclo[1.1.1]pentan-1-yl}ethyl)amino]methyl}-1H-indol-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-({2-[(tert-butylamino)methyl]-1H-indol-6-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

4-(1-{[2-({2-azaspiro[3.3]heptanean-2-yl}methyl)-1H-indol-6-yl]methyl}-1H-1,2,3-triazol-4-yl)-1H-indazole

N-{[2-(2-{2-azaspiro[3.3]heptanean-2-yl}ethyl)-1H-indol-6-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

({3-fluorobicyclo[1.1.1]pentan-1-yl}methyl)({6-[(4-{imidazo[1,5-a]pyridin-8-yl}-1H-1,2,3-triazol-1-yl)methyl]-1H-indol-2-yl}methyl)amine

N-[(2-{[({3-fluorobicyclo[1.1.1]pentan-1-yl}methyl)amino]methyl}-1H-indol-6-yl)methyl]-5-oxo-5H-[1,3]thiazolo[3,2-a]pyrimidine-7-carboxamide

N-[(2-{[({bicyclo[1.1.1]pentan-1-yl}methyl)amino]methyl}-1H-pyrrolo[3,2-b]pyridin-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[({3-fluorobicyclo[1.1.1]pentan-1-yl}methyl)amino]methyl}-1H-pyrrolo[3,2-b]pyridin-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[(cyclobutylmethyl)amino]methyl}-1H-pyrrolo[3,2-b]pyridin-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[({3-methylbicyclo[1.1.1]pentan-1-yl}methyl)amino]methyl}-1H-pyrrolo[3,2-c]pyridin-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[(cyclobutylmethyl)amino]methyl}-1H-pyrrolo[3,2-c]pyridin-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[({bicyclo[1.1.1]pentan-1-yl}methyl)amino]methyl}-1H-pyrrolo[3,2-c]pyridin-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[({3-fluorobicyclo[1.1.1]pentan-1-yl}methyl)amino]methyl}-1H-pyrrolo[3,2-c]ryridine-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[(cyclobutylmethyl)amino]methyl}-1H-indol-6-yl)methyl]-4-oxo-4H,6H,7H,8H,9H-pyrido[1,2-a]pyrimidine-2-carboxamide

(cyclobutylmethyl)({6-[(4-{1H-pyrrolo[2,3-b]pyridin-5-yl}-1H-imidazol-1-yl)methyl]-1H-indol-2-yl}methyl)amine

(cyclobutylmethyl)({6-[(4-{imidazo[1,5-a]pyridin-8-yl}-1H-1,2,3-triazol-1-yl)methyl]-1H-indol-2-yl}methyl)amine

N-[(2-{[(2,2-dimethylpropyl)amino]methyl}-1H-indol-6-yl)methyl]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide

N-[(2-{[(cyclobutylmethyl)amino]methyl}-1H-indol-6-yl)methyl]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide

(cyclobutylmethyl)({6-[(4-{1H-pyrrolo[2,3-b]pyridin-5-yl}-1H-1,2,3-triazol-1-yl)methyl]-1H-indol-2-yl}methyl)amine

N-[[2-(2-azabicyclo[2.2.1]heptanean-2-ylmethyl)-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(3-fluoro-1-bicyclo[1.1.1]pentanyl)methyl]-1-[6-[(4-imidazo[1,5-a]pyridin-8-yltriazol-1-yl)methyl]-1H-pyrrolo[3,2-c]pyridin-2-yl]methanamine

(cyclobutylmethyl)[(6-{[1-(1H-indazol-4-yl)-1H-1,2,3-triazol-4-yl]methyl}-1H-indol-2-yl)methyl]amine

[(3,3-difluorocyclobutyl)methyl][(6-{[1-(1H-indazol-4-yl)-1H-1,2,3-triazol-4-yl]methyl}-1H-indol-2-yl)methyl]amine

(cyclobutylmethyl)[(6-{[1-(isoquinolin-4-yl)-1H-1,2,3-triazol-4-yl]methyl}-1H-indol-2-yl)methyl]amine

(cyclobutylmethyl)({6-[(1-{imidazo[1,5-a]pyridin-8-yl}-1H-1,2,3-triazol-4-yl)methyl]-1H-indol-2-yl}methyl)amine.

3-[1-({2-[({(Bicyclo[1.1.1]pent-1-yl)methyl}amino)methyl]-1H-indol-6-yl}methyl)-1H-1,2,3-triazol-4-yl]-5-methoxy-2-pyridinecarbonitrile;

3-[1-({2-[({(3-Fluorobicyclo[1.1.1]pent-1-yl)methyl}amino)methyl]-1H-indol-6-yl}methyl)-1H-1,2,3-triazol-4-yl]-5-methoxy-2-pyridinecarbonitrile;

5-Methoxy-3-[1-({2-[({(3-methylbicyclo[1.1.1]pent-1-yl)methyl}amino)methyl]-1H-indol-6-yl}methyl)-1H-1,2,3-triazol-4-yl]-2-pyridinecarbonitrile;

3-{1-[(2-{[(Cyclobutylmethyl)amino]methyl}-1H-indol-6-yl)methyl]-1H-1,2,3-triazol-4-yl}-5-methoxy-2-pyridinecarbonitrile;

3-{1-[(2-{(6-Aza-6-spiro[3.4]octyl)methyl}-1H-indol-6-yl)methyl]-1H-1,2,3-triazol-4-yl}-5-methoxy-2-pyridinecarbonitrile;

3-[1-({2-[(4,4-Dimethyl-1-piperidyl)methyl]-1H-indol-6-yl}methyl)-1H-1,2,3-triazol-4-yl]-5-methoxy-2-pyridinecarbonitrile;

N-((2-((6-azaspiro[3.4]octan-6-yl)methyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

3-(1-((2-(((cyclobutylmethyl)amino)methyl)-1H-indol-6-yl)methyl)-1H-1,2,3-triazol-4-yl)-5-fluoropicolinonitrile;

1-cyclobutyl-N-((6-((4-(5-methoxypyridin-3-yl)-1H-1,2,3-triazol-1-yl)methyl)-1H-indol-2-yl)methyl)methanamine;

5-chloro-3-(1-((2-(((cyclobutylmethyl)amino)methyl)-1H-indol-6-yl)methyl)-1H-1,2,3-triazol-4-yl)picolinonitrile; and

2-((6-azaspiro[3.4]octan-6-yl)methyl)-6-((4-(imidazo[1,5-a]pyridin-8-yl)-1H-1,2,3-triazol-1-yl)methyl)-1H-pyrrolo[3,2-c]pyridine.

[0039c] In yet another aspect, the present disclosure refers to a pharmaceutical composition comprising a compound as disclosed herein, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

[0039d] In a further aspect, the present disclosure refers to a compound as disclosed herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as disclosed herein, for use in:

(a) therapy;

(b) the treatment of a proliferative condition;

(c) the treatment of cancer;

(d) the treatment of leukaemia;

(e) the treatment of an autoimmune disease;

(f) the treatment of a neurological disease;

(g) the treatment of an inflammatory disease;

(h) the treatment of an infectious disease; or

(i) the treatment of a disease related to the re-activation of the silenced X-chromosome.

[0039e] In another aspect, the present disclosure refers to a use of a compound as disclosed herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as disclosed herein, in the manufacture of a medicament for

(a) the treatment of a proliferative condition;

(b) the treatment of cancer;

(c) the treatment of leukaemia;

(d) the treatment of an autoimmune disease;

(e) the treatment of a neurological disease;

(f) the treatment of an inflammatory disease;

(g) the treatment of an infectious disease; or

(h) the treatment of a disease related to the re-activation of the silenced X-chromosome.

[0040] In one ~~aspect~~example, the present ~~invention~~disclosure provides a compound as defined herein, or a pharmaceutically acceptable salt thereof.

[0041] In another ~~aspect~~example, the present ~~invention~~disclosure provides a pharmaceutical composition as defined herein which comprises a compound as defined herein, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

[0042] In another ~~aspect~~example, the present ~~invention~~disclosure provides a compound as defined herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as defined herein, for use in therapy.

[0043] In another ~~aspect~~example, the present ~~invention~~disclosure provides a compound as defined herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as defined herein, for use in the treatment of a proliferative condition.

[0044] In another ~~aspect~~example, the present ~~invention~~disclosure provides a compound as defined herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as defined herein, for use in the treatment of cancer. In a particular ~~embodiment~~example, the cancer is a human cancer.

[0045] In another ~~aspect~~example, the present ~~invention~~disclosure provides a compound as defined herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as defined herein, for use in the inhibition of METTL3 activity.

[0046] In another ~~aspect~~example, the present ~~invention~~disclosure provides a compound as defined herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as defined herein, for use in promoting an immune response (e.g. anti-viral or anti-tumour immune response).

[0047] In another ~~aspect~~example, the present ~~invention~~disclosure provides a compound as defined herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as defined herein, for use in increasing an innate immune response in a subject.

[0048] In another ~~aspect~~example, the present ~~invention~~disclosure provides a compound as defined herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as defined herein, for use in increasing or enhancing an anti-tumour immune response during immune-oncology therapy.

[0049] In another ~~aspect~~example, the present ~~invention~~disclosure provides a compound as defined herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as defined herein, for use in the treatment of an autoimmune disease.

[0050] In another ~~aspect~~example, the present ~~invention~~disclosure provides a compound as defined herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as defined herein, for use in the treatment of a neurological disease.

[0051] In another ~~aspect~~example, the present ~~invention~~disclosure provides a compound as defined herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as defined herein, for use in the treatment of an infectious disease.

[0052] In another ~~aspect~~example, the present ~~invention~~disclosure provides a compound as defined herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as defined herein, for use in the treatment of a viral infection. Suitably, the viral infection is a RNA viral infection. Suitably, the viral infection is human papillomavirus (HPV) or hepatitis.

[0053] In another ~~aspect~~example, the present ~~invention~~disclosure provides a compound as defined herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as defined herein, for use in the treatment of an inflammatory disease.

[0054] In another ~~aspect~~example, the present ~~invention~~disclosure provides the use of a compound as defined herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of a proliferative condition.

[0055] In another ~~aspect~~example, the present ~~invention~~disclosure provides the use of a compound as defined herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of cancer. In a particular ~~embodiment~~example, the medicament is for use in the treatment of human cancers.

[0056] In another ~~aspect~~example, the present ~~invention~~disclosure provides the use of a compound as defined herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the inhibition of METTL3 activity.

[0057] In another ~~aspect~~example, the present ~~invention~~disclosure provides the use of a compound as defined herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for promoting an immune response (e.g. anti-viral or anti-tumour immune response).

[0058] In another ~~aspect~~example, the present ~~invention~~disclosure provides the use of a compound as defined herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for for use in increasing an innate immune response in a subject.

[0059] In another ~~aspect~~example, the present ~~invention~~disclosure provides the use of a compound as defined herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in increasing or enhancing an anti-tumour immune response during immune-oncology therapy.

[0060] In another ~~aspect~~example, the present ~~invention~~disclosure provides the use of a compound as defined herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of an autoimmune disease.

[0061] In another ~~aspect~~example, the present ~~invention~~disclosure provides the use of a compound as defined herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of a neurological disease.

[0062] In another ~~aspect~~example, the present ~~invention~~disclosure provides the use of a compound as defined herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of an infectious disease.

[0063] In another ~~aspect~~example, the present ~~invention~~disclosure provides the use of a compound as defined herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of a viral infection. Suitably, the viral infection is a RNA viral infection. Suitably, the viral infection is human papillomavirus (HPV) or hepatitis.

[0064] In another ~~aspect~~example, the present ~~invention~~disclosure provides the use of a compound as defined herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of an inflammatory disease.

[0065] In another ~~aspect~~example, the present ~~invention~~disclosure provides a method of inhibiting METTL3 activity *in vitro* or *in vivo*, said method comprising contacting a cell with an effective amount of a compound as defined herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as defined herein.

[0066] In another ~~aspect~~example, the present ~~invention~~disclosure provides a method of inhibiting cell proliferation *in vitro* or *in vivo*, said method comprising contacting a cell with an effective amount of a compound as defined herein, or a pharmaceutically acceptable salt, or a pharmaceutical composition as defined herein.

[0067] In another ~~aspect~~example, the present ~~invention~~disclosure provides a method of inhibiting metastasis *in vitro* or *in vivo*, said method comprising contacting a cell with an effective amount of a compound as defined herein, or a pharmaceutically acceptable salt, or a pharmaceutical composition as defined herein.

[0068] In another ~~aspect~~example, the present ~~invention~~disclosure provides a method of promoting an immune response (e.g. anti-viral or anti-tumour immune response) in a subject in need thereof, said method comprising administering to the subject a therapeutically effective amount of a compound as defined herein, or a pharmaceutically acceptable salt, or a pharmaceutical composition as defined herein.

[0069] In another ~~aspect~~example, the present ~~invention~~disclosure provides a method of increasing an innate immune response in a subject in need thereof, said method comprising administering to the subject a therapeutically effective amount of a compound as defined herein, or a pharmaceutically acceptable salt, or a pharmaceutical composition as defined herein.

[0070] In another ~~aspect~~example, the present ~~invention~~disclosure provides a method of increasing or enhancing an anti-tumour immune response during immune-oncology therapy, said method comprising administering to a subject in need thereof a therapeutically effective amount of a compound as defined herein, or a pharmaceutically acceptable salt, or a pharmaceutical composition as defined herein.

[0071] In another ~~aspect~~example, the present ~~invention~~disclosure provides a method of treating a proliferative disorder, said method comprising administering to a subject in need thereof a therapeutically effective amount of a compound as defined herein, or a pharmaceutically acceptable salt, or a pharmaceutical composition as defined herein.

[0072] In another ~~aspect~~example, the present ~~invention~~disclosure provides a method of treating cancer, said method comprising administering to a subject in need thereof a therapeutically effective amount of a compound as defined herein, or a pharmaceutically acceptable salt, or a pharmaceutical composition as defined herein.

[0073] In another ~~aspect~~example, the present ~~invention~~disclosure provides a method of treating an autoimmune disease, said method comprising administering to a subject in need thereof a therapeutically effective amount of a compound as defined herein, or a pharmaceutically acceptable salt, or a pharmaceutical composition as defined herein.

[0074] In another ~~aspect~~example, the present ~~invention~~disclosure provides a method of treating a neurological disease, said method comprising administering to a subject in need thereof a therapeutically effective amount of a compound as defined herein, or a pharmaceutically acceptable salt, or a pharmaceutical composition as defined herein.

[0075] In another ~~aspect~~example, the present ~~invention~~disclosure provides a method of treating an infectious disease, said method comprising administering to a subject in need thereof a therapeutically effective amount of a compound as defined herein, or a pharmaceutically acceptable salt, or a pharmaceutical composition as defined herein.

[0076] In another ~~aspect~~example, the present ~~invention~~disclosure provides a method of treating a viral infection, said method comprising administering to a subject in need thereof a therapeutically effective amount of a compound as defined herein, or a pharmaceutically acceptable salt, or a pharmaceutical composition as defined herein. Suitably, the viral infection is a RNA viral infection. Suitably, the viral infection is human papillomavirus (HPV) or hepatitis.

[0077] In another ~~aspect~~example, the present ~~invention~~disclosure provides a method of treating an inflammatory disease, said method comprising administering to a subject in need thereof a therapeutically effective amount of a compound as defined herein, or a pharmaceutically acceptable salt, or a pharmaceutical composition as defined herein.

[0078] In one ~~aspect~~example, the present ~~invention~~disclosure provides a combination comprising a compound as defined herein, or a pharmaceutically acceptable salt thereof, with one or more additional therapeutic agents.

[0079] The present ~~invention~~disclosure further provides a method of synthesising a compound, or a pharmaceutically acceptable salt, as defined herein.

[0080] In another ~~aspect~~example, the present ~~invention~~disclosure provides a compound as defined herein, or a pharmaceutically acceptable salt, obtainable by, or obtained by, or directly obtained by a method of synthesis as defined herein.

[0081] In another ~~aspect~~example, the present ~~invention~~disclosure provides novel intermediates as defined herein which are suitable for use in any one of the synthetic methods as set out herein.

[0082] Preferred, suitable, and optional features of any one particular ~~aspect~~example of the present ~~invention~~disclosure are also preferred, suitable, and optional features of any other ~~aspect~~example.

DETAILED DESCRIPTION OF THE INVENTION

Definitions

[0083] Unless otherwise stated, the following terms used in the specification and claims have

CLAIMS


1. A compound of formula (I) shown below, or a pharmaceutically acceptable salt thereof:


X – Y – Z


(I)


wherein:


X is selected from:



;


;


;


;


; and



wherein

Q_1 is selected from NH, N-C_{1-4}alkyl, O or S;

Q_{2a} is selected from N or CR_{2a};

Q_{2b} is selected from N or CR_{2b};

Q_{2c} is selected from N or CR_{2c};

Q_{2d} is selected from N or CR_{2d};

Q_3 is selected from N or CR_{1b};

Q_4 is selected from N or CR_{1x};

subject to the proviso that no more than 3 of Q_1, Q_{2a}, Q_{2b}, Q_{2c}, Q_{2d}, Q_3 and Q_4 are nitrogen;

R_{1a} is selected from:

(i) C_{1-4}alkyl or C_{1-4}alkoxy, each of which being optionally subsutited by halo, cyano, hydroxy, C_{3-6}cycloalkyl, a 3 to 6 membered heterocyclyl C_{1-4}alkoxy, C_{1-4}haloalkoxy, aryl or heteroaryl; or

(ii) a group of the formula:

$$-(CR_{1c}R_{1d})_p-NR_{1e}R_{1f};$$

wherein

p is an integer selected from 0, 1, 2 or 3

R_{1c} and R_{1d} are independently selected from:

(i) hydrogen (including deuterium),

(ii) C_{1-6}alkyl which is optionally substituted by one more substituents selected from cyano, oxo, hydroxy, C_{1-4}alkoxy, halo, C_{1-4}haloalkoxy, C_{3-6}cycloalkyl, -O-C_{3-6}cycloalkyl, $NR_{1ca}R_{1da}$ or -$S(O)_{0-2}R_{1ca}R_{1da}$, wherein R_{1ca} and R_{1da} are H or C_{1-2}alkyl; and wherein C_{3-6}cycloalkyl and -O-C_{3-6}cycloalkyl are optionally further subsitutued with halo, cyano or hydroxy;

(iii) C_{3-4}cycloalkyl or 3 to 5 membered heterocyclyl, each of which is optionally substituted by C_{1-4}alkyl, C_{1-4}haloalkyl, cyano, hydroxy, C_{1-2}alkoxy, halo, C_{1-2}haloalkoxy, $NR_{1ca}R_{1da}$ or -$S(O)_{0-2}R_{1ca}R_{1da}$, wherein R_{1ca} and R_{1da} are H or C_{1-2}alkyl;

(iv) or R_{1c} and R_{1d} are linked together such that, together with the carbon atom to which they are attached, they form a 3- to 6-membered cycloalkyl or heterocyclic ring, or a spirocyclic ring system, each of which is optionally substituted by one or more substituents selected from C_{1-2}alkyl, C_{1-2}haloalkyl, cyano, hydroxy, C_{1-2}alkoxy, halo, C_{1-2}haloalkoxy, $NR_{1ca}R_{1da}$ or -$S(O)_{0-2}R_{1ca}R_{1da}$, wherein R_{1ca} and R_{1da} are H or C_{1-2}alkyl;

R_{1e} and R_{1f} are each independently selected from:

(i) hydrogen (including deuterium);

(ii) C_{1-6}alkyl which is optionally substituted by one more substituents selected from cyano, oxo, hydroxy, C_{1-2}alkoxy, halo, C_{1-2}haloalkoxy, $NR_{1ea}R_{1fa}$ or -$S(O)_{0-2}R_{1ea}R_{1fa}$, wherein R_{1ea} and R_{1fa} are H or C_{1-2}alkyl;

(iii) a group with the formula:

$$-(CR_{1g}R_{1h})_q-T_1$$

wherein:

q is 0, 1, 2, 3, 4, 5 or 6;

R_{1g} and R_{1h} are independently selected from:

a) hydrogen;

b) C_{1-6}alkyl which is optionally substituted by one more substituents selected from cyano, hydroxy, C_{1-4}alkoxy, halo, C_{1-4}haloalkoxy, -O-C_{3-6}cycloalkyl, $NR_{1ga}R_{1ha}$ or -$S(O)_{0-2}R_{1ga}R_{1ha}$, wherein R_{1ga} and R_{1ha} are H or C_{1-2}alkyl; and wherein -O-C_{3-6}cycloalkyl is optionally subsitutued with halo, cyano or hydroxy;

c) an aryl-C_{1-6}alkyl, heteroarylC_{1-6}alkyl, C_{3-6}cycloalkyl or C_{3-6}-cycloalkylC_{1-6}alkyl group, each of which is optionally substituted by one or more substituents selected from C_{1-2}-alkyl, cyano, C_{1-2}haloalkyl, hydroxy, C_{1-2}alkoxy, halo, C_{1-2}-haloalkoxy, $NR_{1ga}R_{1ha}$ or -$S(O)_{0-2}R_{1ga}R_{1ha}$, wherein R_{1ga} and R_{1ha} are H or C_{1-2}alkyl; or

d) R_{1g} and R_{1h} are optionally linked together such that, together with the carbon atom to which they are attached, they form a 3- to 6-membered cycloalkyl or heterocyclic ring which is optionally substituted by one or more substituents selected from C_{1-2}alkyl, cyano, C_{1-2}haloalkyl, hydroxy, C_{1-2}alkoxy, halo, C_{1-2}haloalkoxy, $NR_{1ga}R_{1ha}$ or -$S(O)_{0-2}R_{1ga}R_{1ha}$, wherein R_{1ga} and R_{1ha} are H or C_{1-2}alkyl; and

T_1 is selected from hydrogen, halo, C_{1-4}alkyl, C_{1-4}haloalkyl, cyano, hydroxy, $NR_{1t}R_{2t}$ or -$S(O)_{0-2}R_{1t}R_{2t}$ (wherein R_{1t} and R_{2t} are H or C_{1-4}alkyl), C_{3-8}cycloalkyl, C_{2-3}alkenyl, C_{2-3}alkynyl, aryl, heterocyclyl, a mono- or bicyclic heteroaryl, a spirocyclic carbocyclic or heterocyclic ring system, a bridged C_{3-8}cycloalkyl, a bridged bicyclic C_{5-12}cycloalkyl, or a bridged heterocyclic ring system, each of which is optionally substituted by one or more substituents selected from C_{1-2}alkyl, C_{1-2}haloalkyl, cyano, hydroxy, C_{1-2}alkoxy, halo, C_{1-2}-haloalkoxy, C_{3-6}cycloalkyl, $NR_{3t}R_{4t}$ or -$S(O)_{0-2}R_{3t}R_{4t}$, wherein R_{3t} and R_{4t} are H or C_{1-2}alkyl;

(iv) or R_{1e} and R_{1f} are linked such that, together with the nitrogen atom to which they are attached, they form a mono- or bicyclic-heterocyclic ring, which is optionally substituted by one or more substituents selected from C_{1-4}alkyl, C_{1-4}haloalkyl, C_{3-6}cycloalkyl, cyano, hydroxy, C_{1-4}alkoxy, halo, C_{1-4}haloalkoxy, $NR_{1i}R_{1j}$ or -$S(O)_{0-2}R_{1i}R_{1j}$, wherein R_{1i} and R_{1j} are H or C_{1-4}alkyl, and/or the mono- or bicyclic hetereocyclic ring formed by R_{1e} and R_{1f} is optionally spiro-fused to a C_{3-6}cycloalkyl or a heterocyclic ring, which in turn is optionally substituted by one or more substituents selected from C_{1-}

$_4$alkyl, C_{1-4}haloalkyl, C_{3-6}cycloalkyl, cyano, hydroxy, C_{1-4}alkoxy, halo, C_{1-4}haloalkoxy, $NR_{1i}R_{1j}$ or $-S(O)_{0-2}R_{1i}R_{1j}$, wherein R_{1i} and R_{1j} are H or C_{1-4}alkyl; wherein any wherein any alkyl, alkoxy or C_{3-6}cycloalkyl is further optionally substituted by one or more substituents selected from cyano, hydroxy, halo, $NR_{1k}R_{1l}$ or $-S(O)_{0-2}R_{1k}R_{1l}$, wherein R_{1k} and R_{1l} are H or C_{1-4}alkyl

R_{1b} is selected from hydrogen, cyano, halo or C_{1-3} alkyl;

R_{1x} is selected from hydrogen, cyano, halo or C_{1-3} alkyl;

R_{2a}, R_{2b}, R_{2c} and R_{2d} are independently selected from hydrogen, cyano, halo or a group of the formula:

$$-L_{2a}-L_{2b}-Q_2$$


wherein


L_{2a} is absent or C_{1-3}alkylene optionally substituted by C_{1-2} alkyl or oxo;


L_{2b} is absent or selected from O, S, SO, SO_2, $N(R_n)$, C(O), C(O)O, OC(O), $C(O)N(R_n)$, $N(R_n)C(O)$, $N(R_n)C(O)N(R_o)$, $S(O)_2N(R_n)$, or $N(R_n)SO_2$, wherein R_n and R_o are each independently selected from hydrogen or C_{1-2}alkyl; and


Q_2 is hydrogen, cyano, C_{1-6}alkyl, C_{3-6}cycloalkyl, aryl, heterocyclyl or heteroaryl, each of which is optionally substituted by one or more substituents selected from halo, trifluoromethyl, trifluoromethoxy, amino, cyano, hydroxy, amino, carboxy, carbamoyl, sulphamoyl, C_{1-4}alkyl, NR_pR_q, OR_p, $C(O)R_p$, $C(O)OR_p$, $OC(O)R_p$, $C(O)N(R_p)R_q$, $N(R_r)C(O)R_p$, $S(O)_yR_p$ (where y is 0, 1 or 2), $SO_2N(R_p)R_q$, $N(R_r)SO_2R_p$ or $(CH_2)_zNR_pR_q$ (where z is 1, 2 or 3), wherein R_p and R_q are each independently selected from hydrogen or C_{1-4}alkyl;


Y is selected from:















,



,



,



,



,


R3e1
R3e2
n
O
N
N
,

O
N
,

R3f1
R3f2
n
N
O
N
,

R3g1
R3g2
n
N
N
O
,

R3h1
R3h2
n
H
N
N
N
,

R3i1
R3i2
n
N
N
N
,

R3j1
R3j2
n
N
N
N
,

R3k1
R3k2
n
N
N
,

R3l1
R3l2
n
N
N
,

R3m1
R3m2
n
N
N
,

R3n1
R3n2
n
S
N
N

R3o1
R3o2
n
N
N
and



;


,


and


;

wherein:

R_{3a1}, R_{3b1}, R_{3c1}, R_{3d1}, R_{3e1}, R_{3f1}, R_{3g1}, R_{3h1}, R_{3i1}, R_{3j1}, R_{3k1}, R_{3l1}, R_{3m1}, R_{3n1}, R_{3o1}, R_{3p1},R_{3q1}, R_{3r1} and R_{3s1} are independently selected from hydrogen (including deuterium), $C_{1\text{-}6}$alkyl, $C_{3\text{-}4}$ cycloalkyl, hydroxy, and halo; and wherein $C_{1\text{-}6}$alkyl, or $C_{3\text{-}4}$ cycloalkyl is optionally substituted with one or more substituents selected from halo, amino, cyano, and hydroxy;















R_{3a2}, R_{3b2}, R_{3c2}, R_{3d2}, R_{3e2}, R_{3f2}, R_{3g2}, R_{3h2}, R_{3i2}, R_{3j2}, R_{3k2}, R_{3l2}, R_{3m2}, R_{3n2}, R_{3o2}, R_{3p2}-,R_{3q2}, R_{3r2} and R_{3s2} are hydrogen or halo;


with the proviso that R_{3a1}, R_{3b1}, R_{3i1}, R_{3l1}, R_{3o1}, R_{3r1}, R_{3a2}, R_{3b2}, R_{3i2}, R_{3l2}, R_{3o2} and R_{3s1} cannot be halo when n=1 or when n=2 and the carbon atom to which they are attached is linked to an oxygen or nitrogen atom;

or R_{3a1} and R_{3a2}, R_{3b1} and R_{3b2}, R_{3c1} and R_{3c2}, R_{3d1} and R_{3d2}, R_{3e1} and R_{3e2}, R_{3f1} and R_{3f2}, R_{3g1} and R_{3g2}, R_{3h1} and R_{3h2}, R_{3i1} and R_{3i2}, R_{3j1} and R_{3j2}, R_{3k1} and R_{3k2}, R_{3l1} and R_{3l2}, R_{3m1} and R_{3m2}, R_{3n1} and R_{3n2}, R_{3o1} and R_{3o2}, R_{3p1} and R_{3p2}, R_{3q1} and R_{3q2}, or R_{3r1} and R_{3r2} or R_{3s1} and R_{3s2} may be linked such that, together with the carbon atom to which they are attached, they form a spiro-fused $C_{3\text{-}4}$cycloalkyl which is optionally substituted with one or more substituents selected from halo, methyl, amino, cyano, and hydroxy;


n is 0, 1 or 2

Z is selected from:


















A7
RZ1a
RZ3a
N
RY5N
N
RZ2a


,


A7
N
RZ3a
N
RY5N
RZ2a
RZi2e


,



A7
N
RZ3a
N
RY5N
N
RZi2e

,



A7
N
N
N
RY5N
RZ2a
RZi2e

,



A7
N
RY5N
RZ2a
RZi2e


A7
O
N
N
S
RZi2e


,



O
R5
R4
R12
N
R13
RZ9
R6


,



O
R5
R4
R19
N
R22
RZ9
R6

,



,


,


, and


,

wherein:

R_4 is selected from hydrogen, halo, cyano, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4}alkoxy, C_{1-4} haloalkoxy (e.g. hydrogen, halo, cyano and methyl);

R_5 is selected from hydrogen, halo, cyano, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4}alkoxy, C_{1-4} haloalkoxy (e.g. hydrogen, halo, cyano and methyl);

R_6 is selected from hydrogen, halo, cyano, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4}alkoxy, C_{1-4} haloalkoxy (e.g. hydrogen, halo, cyano and methyl);

R_8, R_9, R_{10} and R_{11} are independently selected from hydrogen, NH_2, halo, cyano, C_{1-4} alkoxy, C_{1-4} haloalkoxy, C_{1-6} alkyl, $-CH_2OCH_3$, $-CH_2SO_2CH_3$, $-SO_2CH_3$, $-NHC(O)CH_3$ and $-C(O)NR_{v1}R_{v2}$, wherein R_{v1} and R_{v2} are independently selected from hydrogen and methyl; or

R_9 and R_{10} may be linked together such that, together to the atoms to which they are attached, they form a fused 5- or 6-membered saturated or unsaturated ring system, or R_{10} and R_{11} may be linked together such that, together to the atoms to which they are attached, they form a fused 5- or 6-membered saturated or unsaturated ring system, wherein either of the fused 5- or 6-membered saturated or unsaturated ring system may be optionally subsitutued by one or more substituents selected from C_{1-}

$_2$alkyl, cyano, C_{1-2}haloalkyl, hydroxy, C_{1-2}alkoxy, halo, C_{1-2}haloalkoxy, $NR_{1ia}R_{1ja}$ or -$S(O)_{0-2}R_{1ia}R_{1ja}$, wherein R_{1ia} and R_{1ja} are H or C_{1-2}alky;

R_7 and R_{11N} are independently selected from hydrogen, NH_2, halo, cyano, and C_{1-6} alkyl;

R_{Z1} and R_{Z1a} selected from hydrogen, C_{1-4}alkyl, cyano, halo, C_{1-4}haloalkyl, C_{1-4}haloalkoxy, C_{1-4}alkoxy, C_{3-6}cycloalkyl and -O-C_{3-6}cycloalkyl, wherein C_{3-6}cycloalkyl and -O-C_{3-6}cycloalkyl are optionally subsitutued by one or more of halo, methyl or methoxy;

R_{Z2} and R_{Z2a} are selected from hydrogen, C_{1-4}alkyl, cyano, halo, NH_2 and C_{1-4}alkoxy;

R_{Z3a} is selected from hydrogen, C_{1-4}alkyl, cyano, halo, NH_2 and C_{1-4}alkoxy;

R_{Zi1b} is selected from hydrogen, C_{1-4}alkyl, cyano, halo, NH_2 and C_{1-4}alkoxy;

R_{Zi2e} is selected from hydrogen, C_{1-4}alkyl, cyano, halo, NH_2 and C_{1-4}alkoxy;

R_{Y5N} and R_{Z2N} are selected from hydrogen or C_{1-4}alkyl;

R_{Z9} is selected from hydrogen, halo, cyano, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4}alkoxy, C_{1-4} haloalkoxy;

R_{Z10} is selected from hydrogen, halo, cyano, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4}alkoxy, C_{1-4} haloalkoxy;

R_{Z11} is selected from hydrogen, halo, cyano, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4}alkoxy, C_{1-4} haloalkoxy;

R_{Z12} is selected from hydrogen, halo, cyano, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4}alkoxy, C_{1-4} haloalkoxy;

R_{Z13} is selected from hydrogen, halo, cyano, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4}alkoxy, C_{1-4} haloalkoxy;

R_{Z14} is selected from hydrogen, halo, cyano, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4}alkoxy, C_{1-4} haloalkoxy;

R_{Z15} is selected from hydrogen, halo, cyano, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4}alkoxy, C_{1-4} haloalkoxy;

R_{Z16} is selected from hydrogen, halo, cyano, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4}alkoxy, C_{1-4} haloalkoxy;;

A_1 is selected from CR_{12} and N;

A_2 is selected from CR_{13} and N;

A_5 is selected from CR_{16} and N;

A_6 is selected from CR_{17} and N;

A_7 is selected from CR_{18} and N;

A_8 is selected from $CR_{19}R_{20}$ and NR_{21};


A_9 is selected from $CR_{22}R_{23}$ and NR_{24};

A_{11} is selected from $CR_{28}R_{29}$ and NR_{30};


R_{12} is selected from hydrogen, halo, cyano, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4}alkoxy, C_{1-4} haloalkoxy (e.g. hydrogen, halo, cyano and C_{1-4} alkyl);
R_{13} is selected from hydrogen, halo, cyano, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4}alkoxy, C_{1-4} haloalkoxy (e.g. hydrogen, halo, cyano, methoxy and methyl);
R_{16} and R_{18} are selected from hydrogen, halo, cyano, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4}haloalkyl, C_{1-4}haloalkoxy, C_{3-4}cycloalkyl, a 3- to 4-membered heterocyclyl and C_{3-4}-cycloalkoxy;

R_{17} is selected from hydrogen, halo, cyano, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} alkoxy, C_{1-4} haloalkoxy, C_{2-4} alkenyl, C_{2-4} alkynyl, phenyl, a 5- or 6-membered or heteroaryl, C_{3-6}cycloalkyl, -O-C_{3-6}cycloalkyl, heterocyclyl, -O-heterocyclyl (carbon-linked), -$(OCH_2CH_2)_m$-OCH_3 wherein m is an integer from 1 to 6, NR_qR_r, wherein R_q and R_r are each independently hydrogen, C_{1-5} alkyl, C_{3-6}cycloalkyl, a 3- to 6- membered carbon-linked heterocyclyl, or R_q and R_r are linked together such that, together with the nitrogen atom to which they are attached, they form a 3- to 6-membered heterocyclic ring; wherein any C_{1-5}alkyl, C_{1-4} alkoxy, C_{2-4}alkenyl, C_{2-4}alkynyl , phenyl, 5- or 6-membered or heteroaryl, C_{3-6}cycloalkyl, -O-C_{3-6}cycloalkyl, heterocyclyl or -O-heterocyclyl (carbon-linked)is optionally further substituted by one or more substituents selected from C_{1-2}alkyl, cyano, C_{1-2}haloalkyl, hydroxy, C_{1-2}alkoxy, halo, C_{1-2}haloalkoxy, $NR_{1ea}R_{1fa}$ or -$S(O)_{0-2}R_{1ea}R_{1fa}$, wherein R_{1ea} and R_{1fa} are H or C_{1-2}alkyl;
R_{19} and R_{20} are selected from hydrogen, halo, cyano and C_{1-4} alkyl;
R_{22} and R_{23} are selected from hydrogen, halo, cyano, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4}alkoxy, C_{1-4} haloalkoxy (e.g. hydrogen, halo, cyano and methyl;
R_{28} and R_{29} are selected from hydrogen, halo, methoxy and methyl;
R_{21}, R_{24} and R_{30} are hydrogen or C_{1-4}alkyl.


2. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein X is selected from:




;




;




;




;



;




; and




wherein Q_1, R_{1a}, R_{1b}, R_{1x}, R_{2a}, R_{2b}, R_{2c}, R_{2d} are as defined in claim 1;

3. A compound according to claim 1 or claim 2, optionally wherein X is selected from:



and




;


wherein Q_1, R_{1a}, R_{1b}, R_{2a}, R_{2b} and R_{2d} are as defined in claim 1.

34. A compound according to ~~any one of~~ claim~~s~~ 1 or 2~~to 3~~, or a pharmaceutically acceptable salt thereof, wherein Q_1 is selected from NH or N-C_{1-4}alkyl.


45. A compound according to claim 1 or claim 2, or a pharmaceutically acceptable salt thereof, wherein X is selected from:




;




;




;




;




;




;





;





;





;



;



;



;



;


;


;


;


;


;
and


;

wherein R_{1a} is as defined in claim 1 or claim 2.

56. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R_{1a} is selected from:

(i) C_{1-4}alkyl optionally subsutited by halo, cyano, hydroxy, C_{3-6}cycloalkyl, a 3 to 6 membered heterocyclyl, C_{1-4}alkoxy, C_{1-4}haloalkoxy, aryl or heteroaryl; or

(ii) a group of the formula:

$$-(CR_{1c}R_{1d})_p-NR_{1e}R_{1f}$$

wherein

p is an integer selected from 1 or 2;

R_{1c} and R_{1d} are independently selected from:

(i) hydrogen (including deuterium),

(ii) C_{1-3}alkyl which is optionally substituted by one more substituents selected from cyano, oxo, hydroxy, C_{1-4}alkoxy, halo, C_{1-4}haloalkoxy, -O-C_{3-6}cycloalkyl, $NR_{1ca}R_{1da}$ or -$S(O)_{0-2}R_{1ca}R_{1da}$, wherein R_{1ca} and R_{1da} are H or C_{1-2}alkyl; and wherein -O-C_{3-6}cycloalkyl is optionally subsitutued with halo, cyano or hydroxy;

(iii) or R_{1c} and R_{1d} are linked together such that, together with the carbon atom to which they are attached, they form a 3- to 5-membered cycloalkyl or heterocyclic ring, or a spirocyclic ring system, each of which is optionally substituted by one or more substituents selected from C_{1-2}alkyl, C_{1-2}haloalkyl, cyano, hydroxy, C_{1-2}alkoxy, halo, C_{1-2}-haloalkoxy, $NR_{1ca}R_{1da}$ or -$S(O)_{0-2}R_{1ca}R_{1da}$, wherein R_{1ca} and R_{1da} are H or C_{1-2}alkyl;

R_{1e} and R_{1f} are each independently selected from:

(i) hydrogen (including deuterium);

(ii) C_{1-6}alkyl which is optionally substituted by one more substituents selected from cyano, oxo, hydroxy, C_{1-2}alkoxy, halo, C_{1-2}haloalkoxy, $NR_{1ea}R_{1fa}$ or -$S(O)_{0-2}R_{1ea}R_{1fa}$, wherein R_{1ea} and R_{1fa} are H or C_{1-2}alkyl;

(iii) a group with the formula:

$$–(CR_{1g}R_{1h})_q–T_1$$

wherein:

q is 0, 1, 2 or 3;

R_{1g} and R_{1h} are independently selected from:

a) hydrogen (including deuterium); or

b) C_{1-3}alkyl which is optionally substituted by one more substituents selected from cyano, oxo, hydroxy, C_{1-3}alkoxy, halo, C_{1-4}haloalkoxy, -O-C_{3-4}cycloalkyl, wherein -O-C_{3-4}cycloalkyl is optionally subsitutued with halo, cyano or hydroxy, $NR_{1ca}R_{1da}$ or -$S(O)_{0-2}R_{1ca}R_{1da}$, wherein R_{1ca} and R_{1da} are H or C_{1-2}alkyl$NR_{1ga}R_{1ha}$ or -$S(O)_{0-2}R_{1ga}R_{1ha}$, wherein R_{1ga} and R_{1ha} are H or C_{1-2}alkyl; or

c) or R_{1g} and R_{1h} are optionally linked together such that, together with the carbon atom to which they are attached, they form a 3- to 6-membered cycloalkyl or

heterocyclic ring which is optionally substituted by one or more substituents selected from C_{1-2}alkyl, C_{1-2}-haloalkyl, cyano, hydroxy, C_{1-2}alkoxy, halo, C_{1-2}-haloalkoxy, $NR_{1ga}R_{1ha}$ or $-S(O)_{0-2}R_{1ga}R_{1ha}$, wherein R_{1ga} and R_{1ha} are H or C_{1-2}alkyl;

and T_1 is selected from hydrogen, halo, C_{1-4}alkyl, C_{1-4}haloalkyl, cyano, hydroxy, $NR_{1t}R_{2t}$ or $-S(O)_{0-2}R_{1t}R_{2t}$ (wherein R_{1t} and R_{2t} are H or C_{1-4}alkyl), C_{3-8}cycloalkyl, C_{2-3}alkenyl, C_{2-3}alkynyl, aryl, heterocyclyl, a mono- or bicyclic heteroaryl, a spirocyclic carbocyclic or heterocyclic ring system, a bridged C_{3-8}cycloalkyl, a bridged bicyclic C_{5-12}cycloalkyl, or a bridged heterocyclic ring system, each of which is optionally substituted by one or more substituents selected from C_{1-2}alkyl, C_{1-2}-haloalkyl, cyano, hydroxy, C_{1-2}alkoxy, halo, C_{1-2}haloalkoxy, C_{3-6}cycloalkyl, $NR_{3t}R_{4t}$ or $-S(O)_{0-2}R_{3t}R_{4t}$, wherein R_{3t} and R_{4t} are H or C_{1-2}alkyl;

(iv) or R_{1e} and R_{1f} are linked such that, together with the nitrogen atom to which they are attached, they form a mono- or bicyclic-heterocyclic ring, which is optionally substituted by one or more substituents selected from C_{1-4}alkyl, C_{1-4}haloalkyl, C_{3-6}cycloalkyl, cyano, hydroxy, C_{1-4}alkoxy, halo, C_{1-4}haloalkoxy, $NR_{1i}R_{1j}$ or $-S(O)_{0-2}R_{1i}R_{1j}$, wherein R_{1i} and R_{1j} are H or C_{1-4}alkyl, and/or the mono- or bicyclic hetereocyclic ring formed by R_{1e} and R_{1f} is optionally spiro-fused to a C_{3-6}cycloalkyl or a heterocyclic ring, which is optionally substituted by one or more substituents selected from C_{1-4}alkyl, C_{1-4}haloalkyl, C_{3-6}cycloalkyl, cyano, hydroxy, C_{1-4}alkoxy, halo, C_{1-4}haloalkoxy, $NR_{1i}R_{1j}$ or $-S(O)_{0-2}R_{1i}R_{1j}$, wherein R_{1i} and R_{1j} are H or C_{1-4}alkyl; wherein any alkyl, alkoxy or C_{3-6}cycloalkyl is further optionally substituted by one or more substituents selected from cyano, hydroxy, halo, $NR_{1k}R_{1l}$ or $-S(O)_{0-2}R_{1k}R_{1l}$, wherein R_{1k} and R_{1l} are H or C_{1-4}alkyl.

67. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R_{1a} is a group of the formula:

$$–(CR_{1c}R_{1d})_p–NR_{1e}R_{1f}$$

wherein

p is an integer selected from 1 or 2;

R_{1c} and R_{1d} are independently selected from:

(i) hydrogen (including deuterium), or

(ii) C_{1-3}alkyl which is optionally substituted by one more substituents selected from cyano, oxo, hydroxy, C_{1-3}alkoxy, halo, C_{1-3}haloalkoxy, -O-C_{3-4}cycloalkyl, or NH_2; wherein -O-C_{3-6}cycloalkyl is optionally subsitutued with halo, cyano or hydroxy,

(iii) or R_{1c} and R_{1d} are linked together such that, together with the carbon atom to which they are attached, they form a 3- to 5-membered cycloalkyl or heterocyclic ring, or a spirocyclic ring system, each of which is optionally substituted by one or more substituents selected from C_{1-2}alkyl, C_{1-2}haloalkyl, cyano, hydroxy, C_{1-2}alkoxy, halo, C_{1-2}haloalkoxy, $NR_{1ca}R_{1da}$ or -$S(O)_{0-2}R_{1ca}R_{1da}$, wherein R_{1ca} and R_{1da} are H or C_{1-2}alkyl;

R_{1e} and R_{1f} are each independently selected from:

(i) hydrogen (including deuterium);

(ii) C_{1-6}alkyl which is optionally substituted by one more substituents selected from cyano, hydroxy, C_{1-2}alkoxy, halo, C_{1-2}haloalkoxy and NH_2;

(iii) a group with the formula:

$$–(CR_{1g}R_{1h})_q–T_1$$

wherein:

q is 0, 1, 2 or 3;

R_{1g} and R_{1h} are independently selected from:

a) hydrogen (including deuterium);

b) C_{1-6}alkyl which is optionally substituted by one more substituents selected from cyano, hydroxy, C_{1-4}alkoxy, halo, C_{1-4}haloalkoxy, -O-C_{3-6}cycloalkyl, $NR_{1ca}R_{1da}$ or -$S(O)_{0-2}R_{1ca}R_{1da}$, wherein R_{1ca} and R_{1da} are H or C_{1-2}alkyl$NR_{1ga}R_{1ha}$ or -$S(O)_{0-2}R_{1ga}R_{1ha}$, wherein R_{1ga} and R_{1ha} are H or C_{1-2}alkyl; and wherein -O-C_{3-6}cycloalkyl is optionally subsitutued with halo, cyano or hydroxy; or

c) or R_{1g} and R_{1h} are optionally linked together such that, together with the carbon atom to which they are attached, they form a 3- to 6-membered cycloalkyl or heterocyclic ring which is optionally substituted by one or more substituents selected from C_{1-2}alkyl, C_{1-2}haloalkyl, cyano, hydroxy, C_{1-2}alkoxy, halo, C_{1-2}haloalkoxy, $NR_{1ga}R_{1ha}$ or -$S(O)_{0-2}R_{1ga}R_{1ha}$, wherein R_{1ga} and R_{1ha} are H or C_{1-2}alkyl;

and T_1 is selected from hydrogen, halo, C_{1-4}alkyl, C_{1-4}haloalkyl, cyano, hydroxy, $NR_{1t}R_{2t}$ or -$S(O)_{0-2}R_{1t}R_{2t}$ (wherein R_{1t} and R_{2t} are H or C_{1-4}alkyl), C_{3-8}cycloalkyl, C_{2-3}alkenyl, C_{2-3}alkynyl, aryl, heterocyclyl, a

mono- or bicyclic heteroaryl, a spirocyclic carbocyclic or heterocyclic ring system, a bridged C_{3-8}cycloalkyl, a bridged bicyclic C_{5-12}cycloalkyl, or a bridged heterocyclic ring system, each of which is optionally substituted by one or more substituents selected from C_{1-2}alkyl, C_{1-2}haloalkyl, cyano, hydroxy, C_{1-2}alkoxy, halo, C_{1-2}haloalkoxy, C_{3-6}cycloalkyl, $NR_{3t}R_{4t}$ or $-S(O)_{0-2}R_{3t}R_{4t}$, wherein R_{3t} and R_{4t} are H or C_{1-2}alkyl;

(iv) or R_{1e} and R_{1f} are linked such that, together with the nitrogen atom to which they are attached, they form a mono- or bicyclic-heterocyclic ring, which is optionally substituted by one or more substituents selected from C_{1-4}alkyl, C_{1-4}haloalkyl, C_{3-6}cycloalkyl, cyano, hydroxy, C_{1-4}alkoxy, halo, C_{1-4}haloalkoxy, $NR_{1i}R_{1j}$ or $-S(O)_{0-2}R_{1i}R_{1j}$, wherein R_{1i} and R_{1j} are H or C_{1-4}alkyl, and/or the mono- or bicyclic hetereocyclic ring formed by R_{1e} and R_{1f} is optionally spiro-fused to a C_{3-6}cycloalkyl or a heterocyclic ring, which in turn is optionally substituted by one or more substituents selected from C_{1-4}alkyl, C_{1-4}haloalkyl, C_{3-6}cycloalkyl, cyano, hydroxy, C_{1-4}alkoxy, halo, C_{1-4}haloalkoxy, $NR_{1i}R_{1j}$ or $-S(O)_{0-2}R_{1i}R_{1j}$, wherein R_{1i} and R_{1j} are H or C_{1-4}alkyl.

78. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R_{1a} is a group of the formula:

$$–(CR_{1c}R_{1d})_p–NR_{1e}R_{1f}$$

wherein

R_{1c} and R_{1d} are independently selected from hydrogen (including deuterium) or C_{1-2}alkyl;

R_{1e} is selected from hydrogen (including deuterium) or C_{1-2}alkyl; and

R_{1f} is a group with the formula:

$$–(CR_{1g}R_{1h})_q–T_1$$

wherein:

q is 1;

R_{1g} and R_{1h} are independently selected from hydrogen (including deuterium) or C_{1-2}alkyl;

and T_1 is selected from C_{3-4}cycloalkyl, heterocyclyl, a spirocyclic carbocyclic or heterocyclic ring system, a bridged C_{3-8}cycloalkyl, a bridged bicyclic C_{5-12}cycloalkyl, or a bridged heterocyclic ring system, each of which is optionally substituted by one or more substituents selected from C_{1-2}alkyl, C_{1-2}haloalkyl, cyano, hydroxy, C_{1-2}alkoxy, halo, C_{1-2}haloalkoxy or C_{3-6}cycloalkyl,

wherein any alkyl or alkoxy is optionally further substituted by one or more substituents selected from cyano, hydroxy or halo.

89. A compound according to any one of the preceding claims, wherein R_{1a} is a group of the formula:

$$–(CR_{1c}R_{1d})_p–NR_{1e}R_{1f}$$




wherein












p is 1;


R_{1c} and R_{1d} are independently selected from hydrogen (including deuterium) or C_{1-2}alkyl; and


R_{1e} and R_{1f} are linked such that, together with the nitrogen atom to which they are attached, they form a mono- or bicyclic-heterocyclic ring, which is optionally substituted by one or more substituents selected from C_{1-2}alkyl, C_{1-2}haloalkyl, C_{3-6}cycloalkyl, cyano, hydroxy, C_{1-2}alkoxy, halo or C_{1-2}haloalkoxy, and/or the mono- or bicyclic hetereocyclic ring formed by R_{1e} and R_{1f} is optionally spiro-fused to a C_{3-6}cycloalkyl or a heterocyclic ring, which in turn is optionally substituted by one or more substituents selected from C_{1-2}alkyl, C_{1-2}haloalkyl, cyano, hydroxy, C_{1-2}alkoxy, halo or C_{1-2}haloalkoxy.


910. A compound according to any of claims 1 to 67, wherein R_{1a} is selected from



;

;

;



;

;

;

;

;

;

;

;

,

,

,





,



,



,



,



,



,



,



,



;


;

















;















5


.,




,


,


















,

,

,

,

;

,

,

,

,

,

,

,

,


,

,

,

,

,

,




and .


10[11]. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R_{1b} is selected from hydrogen, halo or C_{1-2} alkyl.

1112. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R_{2a}, R_{2b}, R_{2c} and R_{2d} are independently selected from hydrogen, cyano, halo or C_{1-3}alkyl.

1213. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein Y is selected from:




,




, and ;

wherein n, R_{3a1}, R_{3a2}, R_{3b1}, R_{3b2}, R_{3e1}, R_{3e2}, R_{3i1}, R_{3i2}, R_{3j1} and R_{3j2} are as defined in any one of the preceding claims;


optionally wherein Y is selected from:




,



,
















and





.


1314. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein Z is selected from:



















,


,


,


,


,


and


;

wherein A_1, A_2, A_5, A_6, A_7, A_8, A_9, A_{11}, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11}, R_{11N}, R_{12}, R_{13}, R_{19}, R_{22}, R_{Z1}, R_{Z2}, R_{Z2N}, R_{z9}, R_{Z10}, R_{Z11}, R_{Z12}, R_{Z13}, R_{Z14}, R_{Z15}, R_{Z16}, R_{Z2a}, R_{Z3a}, R_{Z1a}, R_{Zi1b} and R_{Zi2e} are as defined in any one of the preceding claims.

1415. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein:

(i) R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11}, R_{11a}, R_{11b}, R_{Z2}, R_{Z2a}, R_{Z3a}, R_{Zi1b}, R_{Zi2e}, R_{Z9}, R_{Z10}, R_{Z11}, R_{Z12}, R_{Z12a}, R_{Z13}, R_{Z14}, R_{Z15} and R_{Z16} are independently selected from hydrogen, methyl, cyano or halo; and

R_{Y5N}, R_{Z2N} and R_{11N} are selected from methyl or hydrogen;

(ii) R_{Z1} and R_{Z1a} are selected from hydrogen, C_{1-4}alkyl, cyano, halo, C_{1-4}haloalkyl, C_{1-4}haloalkoxy, C_{1-4}alkoxy, C_{3-6}cycloalkyl and -O-C_{3-6}cycloalkyl;

(iii) R_{12}, R_{13}, R_{16}, R_{18}, R_{19}, R_{20}, R_{21}, R_{22}, R_{23}, R_{24} and R_{30} are independently selected from hydrogen, halo, cyano and methyl;

(iv) R_{17} is selected from hydrogen, halo, cyano, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} alkoxy, C_{1-4} haloalkoxy, C_{2-4} alkenyl, C_{2-4} alkynyl, phenyl a 5- or 6-membered or heteroaryl, C_{3-6}cycloalkyl, -O-C_{3-6}cycloalkyl, heterocyclyl, -$(OCH_2CH_2)_m$-OCH_3 wherein m is an integer from 1 to 6, NR_qR_r, wherein R_q and R_r are each independently hydrogen, C_{1-4} alkyl or R_q and R_r are linked together such that, together with the nitrogen atom to which they are attached, they form a 3- to 6-membered heterocyclic ring; ; wherein any C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, phenyl, 5- or 6-membered or heteroaryl, C_{3-6}cycloalkyl, -O-C_{3-6}cycloalkyl, heterocyclyl or -O-heterocyclyl (carbon-linked) is optionally further substituted by one or more substituents selected from C_{1-2}alkyl, cyano, C_{1-2}haloalkyl, hydroxy, C_{1-2}alkoxy, halo, C_{1-2}haloalkoxy, $NR_{1ea}R_{1fa}$ or -$S(O)_{0-2}R_{1ea}R_{1fa}$, wherein R_{1ea} and R_{1fa} are H or C_{1-2}alkyl.


(v) R_{21}, R_{24} and R_{30}, are independently selected from hydrogen or methyl;


(vi) R_{28} and R_{29} are selected from hydrogen or halo, methoxy and methyl.


1516. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R_{17} is selected from hydrogen, halo, cyano, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} alkoxy, C_{1-4} haloalkoxy, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{3-6}cycloalkyl, -O-C_{3-4}cycloalkyl, heterocyclyl, -$(OCH_2CH_2)_m$-OCH_3 wherein m is 1, 2 or 3, NR_qR_r, wherein R_q and R_r are each independently hydrogen or C_{1-2} alkyl;


wherein any C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl or ring system is optionally substituted by one or more substituents selected from C_{1-2}alkyl, C_{1-2}haloalkyl, cyano, hydroxy, C_{1-2}alkoxy, halo and C_{1-2}haloalkoxy.


1617. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein Z is selected from:





,


,



,


,



,


,



,



;




; and




A_1, A_2, A_5, A_6, A_7, A_8, A_9, A_{11}, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11}, R_{Y5N}, R_{Z1}, R_{Z2}, R_{Z10}, R_{Z12}, R_{Z13}, R_{Z14}, R_{Z15}, R_{Z16}, R_{Z2a}, R_{Z3a}, R_{Z1a}, R_{Zi1b} and R_{Zi2e} are as defined in any one of the preceding claims.

17~~18~~. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:

X is





or





;

Y is selected from:




,



,



and



; and

Z is selected from:




,



,


,



,



,



and



wherein:


(i) R_{1a}, R_{1b}, R_{2a}, R_{2b} and R_{2d} are as defined in any one of the preceding claims;

(ii) R_{3a1}, R_{3a2}, R_{3b1}, R_{3b2}, R_{3i1}, R_{3i2}, R_{3j1}, R_{3j2} and n are as defined in any one of the preceding claims; and


(iii) A_1, A_2, A_5, A_6, A_7, R_4, R_5, R_6, R_8, R_9, R_{10}, R_{11}, R_{Z1}, R_{Z2}, R_{Z10}, R_{Z12}, R_{Z13}, R_{Z14}, R_{Z15}, R_{Z16}, R_{Z2a}, R_{Z3a}, R_{Zi2e}, R_{Zi1b} and R_{Z2} are as defined in any one of the preceding claims; or.


~~19. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:~~

X is



;

Y is  ; and

Z is 

(i) wherein R_{1a}, $R_{1b,}$ R_{2a}, R_{2b} and R_{2d} are as defined in any one of the preceding claims;

(ii) n, R_{3a1} and R_{3a2} are as defined defined in any one of the preceding claims; and

(iii) A_1, A_2, R_4, R_5 and R_6 are as defined defined in any one of the preceding claims.

18~~20~~. A compound, or a pharmaceutically acceptable salt thereof, selected from any one of the following:

N-({2-[(4,4-dimethylpiperidin-1-yl)methyl]-1H-indol-6-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[(cyclobutylmethyl)amino]methyl}-1H-indol-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[[(3,3-difluorocyclobutyl)methylamino]methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[[(1-hydroxycyclobutyl)methylamino]methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[[(1-fluorocyclobutyl)methylamino]methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[[(1-methylcyclopropyl)methylamino]methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide.

N-[[2-(2-azabicyclo[2.1.1]hexan-2-ylmethyl)-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-(3-azabicyclo[3.1.1]heptanean-3-ylmethyl)-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[[2-(hydroxymethyl)pyrrolidin-1-yl]methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-(morpholinomethyl)-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide
N-[[2-[(1-adamantylamino)methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide
4-oxo-N-[[2-(1-piperidylmethyl)-1H-indol-6-yl]methyl]pyrido[1,2-a]pyrimidine-2-carboxamide
N-[[2-[(4-fluoro-1-piperidyl)methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide
4-oxo-N-[[2-[[[rac-(1S,2S,4S)-7-oxabicyclo[2.2.1]heptane-5-en-2-yl]methylamino]methyl]-1H-indol-6-yl]methyl]pyrido[1,2-a]pyrimidine-2-carboxamide
N-[[2-[[(1-hydroxycyclopentyl)methylamino]methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide
4-oxo-N-[[2-[[[rac-(1S,2R,4S)-7-oxabicyclo[2.2.1]heptane-5-en-2-yl]methylamino]methyl]-1H-indol-6-yl]methyl]pyrido[1,2-a]pyrimidine-2-carboxamide
N-[[2-[(1-bicyclo[1.1.1]pentanylamino)methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide
N-[[2-[(cyclobutylamino)methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide
N-({2-[({bicyclo[2.2.1]heptanean-2-yl}amino)methyl]-1H-indol-6-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide
N-[[2-[(cyclopropylamino)methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide
N-[[2-(2-azabicyclo[2.2.2]octan-2-ylmethyl)-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide
N-[[2-[[(2,2-difluorocyclopropyl)methylamino]methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide
N-[(2-{[({3-fluorobicyclo[1.1.1]pentan-1-yl}methyl)amino]methyl}-1H-indol-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide
N-[[2-[(cyclohexylmethylamino)methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide
N-[[2-[[(1-hydroxycyclohexyl)methylamino]methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide
N-[[2-[(cyclopentylamino)methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide
N-[[2-[(cyclopentylmethylamino)methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide
N-[[2-[[(1-methoxycyclobutyl)methylamino]methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[(isobutylamino)methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[(cyclohexylamino)methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[(cyclopropylmethylamino)methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

4-oxo-N-[[2-[(prop-2-ynylamino)methyl]-1H-indol-6-yl]methyl]pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[(oxetan-2-ylmethylamino)methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[(2,2-dimethylpropylamino)methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[(1-bicyclo[1.1.1]pentanylmethylamino)methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-{[2-({[(1S,2S)-2-hydroxycyclopentyl]amino}methyl)-1H-indol-6-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-{[2-({[(1R,2R)-2-hydroxycyclopentyl]amino}methyl)-1H-indol-6-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-{[2-({[(1S,2R)-2-hydroxycyclopentyl]amino}methyl)-1H-indol-6-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-{[2-({[(1R,2S)-2-hydroxycyclopentyl]amino}methyl)-1H-indol-6-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[(cyclopropylmethylamino)methyl]-5-fluoro-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[(cyclobutylmethylamino)methyl]-5-fluoro-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

4-oxo-N-[[2-[(2,2,2-trifluoroethylamino)methyl]-1H-indol-6-yl]methyl]pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[N-(cyclobutylmethyl)acetamido]methyl}-1H-indol-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

4-oxo-N-{[2-(piperidin-2-yl)-1H-indol-6-yl]methyl}-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[(cyclobutylmethyl)amino]methyl}-3-fluoro-1H-indol-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[(cyclobutylmethyl)amino]methyl}-1-methyl-1H-indol-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[(Cyclobutylmethylamino)-dideuterio-methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[(cyclobutylmethylamino)methyl]-1H-indol-6-yl]methyl]-1H-indazole-4-carboxamide
N-[[2-[(cyclobutylmethylamino)methyl]-1H-pyrrolo[3,2-b]pyridin-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide
N-(1H-indol-6-ylmethyl)-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide
N-(1H-indol-2-ylmethyl)-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide
N-(indolizin-2-ylmethyl)-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide
N-[(6-{[4-(1H-indazol-4-yl)-1H-1,2,3-triazol-1-yl]methyl}-1H-indol-2-yl)methyl]cyclopropanamine
(1R,2S)-2-[[6-[[4-(1H-indazol-4-yl)triazol-1-yl]methyl]-1H-indol-2-yl]methylamino]cyclopentanol
N-[[6-[[4-(1H-indazol-4-yl)triazol-1-yl]methyl]-1H-indol-2-yl]methyl]cyclopentanamine
N-(cyclopropylmethyl)-1-[6-[[4-(1H-indazol-4-yl)triazol-1-yl]methyl]-1H-indol-2-yl]methanamine
1-[[[6-[[4-(1H-indazol-4-yl)triazol-1-yl]methyl]-1H-indol-2-yl]methylamino]methyl]cyclobutanol
N-(cyclobutylmethyl)-1-[6-[[4-(1H-indazol-4-yl)triazol-1-yl]methyl]-1H-indol-2-yl]methanamine
N-(cyclobutylmethyl)-1-[6-[[4-(1H-indazol-4-yl)triazol-1-yl]methyl]-1H-pyrrolo[3,2-b]pyridin-2-yl]methanamine
N-(cyclobutylmethyl)-1-[6-[[4-(1H-indazol-4-yl)triazol-1-yl]methyl]-1H-pyrrolo[3,2-c]pyridin-2-yl]methanamine
N-(cyclobutylmethyl)-1-[6-[[4-(1H-indazol-4-yl)triazol-1-yl]methyl]-1H-pyrrolo[3,2-c]pyridin-2-yl]methanamine
2-[1-[[2-[(cyclobutylmethylamino)methyl]-1H-indol-6-yl]methyl]triazol-4-yl]pyrido[1,2-a]pyrimidin-4-one
N-(cyclobutylmethyl)-1-[6-[[4-(6-methoxyimidazo[1,5-a]pyridin-8-yl)triazol-1-yl]methyl]-1H-indol-2-yl]methanamine
N-(cyclobutylmethyl)-1-[6-[[4-(1H-indazol-4-yl)imidazol-1-yl]methyl]-1H-indol-2-yl]methanamine
N-(cyclobutylmethyl)-1-[6-[[3-(1H-indazol-4-yl)-1,2,4-oxadiazol-5-yl]methyl]-1H-indol-2-yl]methanamine
N-[[2-(2-azaspiro[3.3]heptanean-2-ylmethyl)-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide
N-[[2-[(benzylamino)methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide
N-[[2-(3-azabicyclo[3.1.0]hexan-3-ylmethyl)-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide
N-[[2-[[cyclobutylmethyl(methyl)amino]methyl]-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[[2-[(cyclobutylmethylamino)methyl]-1H-pyrrolo[2,3-b]pyridin-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[(cyclobutylmethyl)amino]methyl}-1H-1,3-benzodiazol-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[(but-2-yn-1-yl)amino]methyl}-1H-indol-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[(3-cyclopropylprop-2-yn-1-yl)amino]methyl}-1H-indol-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-({2-[({bicyclo[3.1.0]hexan-6-yl}amino)methyl]-1H-indol-6-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[({bicyclo[2.1.1]hexan-1-yl}methyl)amino]methyl}-1H-indol-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[({3-methylbicyclo[1.1.1]pentan-1-yl}methyl)amino]methyl}-1H-indol-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-({2-[(3-methylazetidin-1-yl)methyl]-1H-indol-6-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-({2-[(3-fluoroazetidin-1-yl)methyl]-1H-indol-6-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-({2-[(azetidin-1-yl)methyl]-1H-indol-6-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-{[2-({2-azaspiro[3.4]octan-2-yl}methyl)-1H-indol-6-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-({2-[(3-hydroxyazetidin-1-yl)methyl]-1H-indol-6-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-({2-[(3,3-dimethylazetidin-1-yl)methyl]-1H-indol-6-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

4-oxo-N-[(2-{[3-(2,2,2-trifluoroethoxy)azetidin-1-yl]methyl}-1H-indol-6-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[3-(difluoromethyl)azetidin-1-yl]methyl}-1H-indol-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-({2-[(3-methoxyazetidin-1-yl)methyl]-1H-indol-6-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[3-(tert-butoxy)azetidin-1-yl]methyl}-1H-indol-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

4-oxo-N-[(2-{[3-(trifluoromethyl)azetidin-1-yl]methyl}-1H-indol-6-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-({2-[(3-ethoxyazetidin-1-yl)methyl]-1H-indol-6-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-{[2-({2-azaspiro[3.5]nonan-2-yl}methyl)-1H-indol-6-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-({2-[(2-methylazetidin-1-yl)methyl]-1H-indol-6-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-({2-[(3,3-dimethylpyrrolidin-1-yl)methyl]-1H-indol-6-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-{[2-({6-fluoro-2-azaspiro[3.3]heptanean-2-yl}methyl)-1H-indol-6-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-{[2-({6,6-difluoro-2-azaspiro[3.3]heptanean-2-yl}methyl)-1H-indol-6-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-({2-[(3-cyclobutylazetidin-1-yl)methyl]-1H-indol-6-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-({2-[(3-cyclopropylazetidin-1-yl)methyl]-1H-indol-6-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-({2-[(3-tert-butylazetidin-1-yl)methyl]-1H-indol-6-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[(1-tert-butylcyclopropyl)amino]methyl}-1H-indol-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-{[2-({[(3-methylcyclobutyl)methyl]amino}methyl)-1H-indol-6-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

4-oxo-N-[(2-{[(2,3,3-trimethylbutan-2-yl)amino]methyl}-1H-indol-6-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[({imidazo[1,2-a]pyridin-2-yl}methyl)amino]methyl}-1H-indol-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-({2-[(3,3-diethylazetidin-1-yl)methyl]-1H-indol-6-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

4-oxo-N-[(2-{[(pent-3-yn-1-yl)amino]methyl}-1H-indol-6-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-{[2-({6-azaspiro[3.4]octan-6-yl}methyl)-1H-indol-6-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-({2-[(2,2-dimethylpyrrolidin-1-yl)methyl]-1H-indol-6-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-{[2-({octahydrocyclopenta[c]pyrrol-2-yl}methyl)-1H-indol-6-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-{[2-({5-azaspiro[2.4]heptanean-5-yl}methyl)-1H-indol-6-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[({3-methoxybicyclo[1.1.1]pentan-1-yl}methyl)amino]methyl}-1H-indol-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

4-oxo-N-[(2-{[({spiro[2.2]pentan-1-yl}methyl)amino]methyl}-1H-indol-6-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

4-oxo-N-({2-[({spiro[2.3]hexan-1-yl}amino)methyl]-1H-indol-6-yl}methyl)-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[({3-cyanobicyclo[1.1.1]pentan-1-yl}methyl)amino]methyl}-1H-indol-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-{[2-({1-oxa-6-azaspiro[3.4]octan-6-yl}methyl)-1H-indol-6-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-{[2-({2-azaspiro[4.4]nonan-2-yl}methyl)-1H-indol-6-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[(1-methylcyclopentyl)amino]methyl}-1H-indol-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-{[2-(hydroxymethyl)-1H-indol-6-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[(1-cyclobutylcyclopropyl)amino]methyl}-1H-indol-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-{[2-({[(1-methylcyclobutyl)methyl]amino}methyl)-1H-indol-6-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

4-oxo-N-[(2-{[({spiro[2.3]hexan-5-yl}methyl)amino]methyl}-1H-indol-6-yl)methyl]-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-({2-[({[3-(fluoromethyl)bicyclo[1.1.1]pentan-1-yl]methyl}amino)methyl]-1H-indol-6-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[(1-{3-fluorobicyclo[1.1.1]pentan-1-yl}ethyl)amino]methyl}-1H-indol-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-({2-[(tert-butylamino)methyl]-1H-indol-6-yl}methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

4-(1-{[2-({2-azaspiro[3.3]heptanean-2-yl}methyl)-1H-indol-6-yl]methyl}-1H-1,2,3-triazol-4-yl)-1H-indazole

N-{[2-(2-{2-azaspiro[3.3]heptanean-2-yl}ethyl)-1H-indol-6-yl]methyl}-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

({3-fluorobicyclo[1.1.1]pentan-1-yl}methyl)({6-[(4-{imidazo[1,5-a]pyridin-8-yl}-1H-1,2,3-triazol-1-yl)methyl]-1H-indol-2-yl}methyl)amine

N-[(2-{[({3-fluorobicyclo[1.1.1]pentan-1-yl}methyl)amino]methyl}-1H-indol-6-yl)methyl]-5-oxo-5H-[1,3]thiazolo[3,2-a]pyrimidine-7-carboxamide

N-[(2-{[({bicyclo[1.1.1]pentan-1-yl}methyl)amino]methyl}-1H-pyrrolo[3,2-b]pyridin-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[({3-fluorobicyclo[1.1.1]pentan-1-yl}methyl)amino]methyl}-1H-pyrrolo[3,2-b]pyridin-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[(cyclobutylmethyl)amino]methyl}-1H-pyrrolo[3,2-b]pyridin-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[({3-methylbicyclo[1.1.1]pentan-1-yl}methyl)amino]methyl}-1H-pyrrolo[3,2-c]pyridin-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[(cyclobutylmethyl)amino]methyl}-1H-pyrrolo[3,2-c]pyridin-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[({bicyclo[1.1.1]pentan-1-yl}methyl)amino]methyl}-1H-pyrrolo[3,2-c]pyridin-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[({3-fluorobicyclo[1.1.1]pentan-1-yl}methyl)amino]methyl}-1H-pyrrolo[3,2-c]501yridine-6-yl)methyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(2-{[(cyclobutylmethyl)amino]methyl}-1H-indol-6-yl)methyl]-4-oxo-4H,6H,7H,8H,9H-pyrido[1,2-a]pyrimidine-2-carboxamide

(cyclobutylmethyl)({6-[(4-{1H-pyrrolo[2,3-b]pyridin-5-yl}-1H-imidazol-1-yl)methyl]-1H-indol-2-yl}methyl)amine

(cyclobutylmethyl)({6-[(4-{imidazo[1,5-a]pyridin-8-yl}-1H-1,2,3-triazol-1-yl)methyl]-1H-indol-2-yl}methyl)amine

N-[(2-{[(2,2-dimethylpropyl)amino]methyl}-1H-indol-6-yl)methyl]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide

N-[(2-{[(cyclobutylmethyl)amino]methyl}-1H-indol-6-yl)methyl]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide

(cyclobutylmethyl)({6-[(4-{1H-pyrrolo[2,3-b]pyridin-5-yl}-1H-1,2,3-triazol-1-yl)methyl]-1H-indol-2-yl}methyl)amine

N-[[2-(2-azabicyclo[2.2.1]heptanean-2-ylmethyl)-1H-indol-6-yl]methyl]-4-oxo-pyrido[1,2-a]pyrimidine-2-carboxamide

N-[(3-fluoro-1-bicyclo[1.1.1]pentanyl)methyl]-1-[6-[(4-imidazo[1,5-a]pyridin-8-yltriazol-1-yl)methyl]-1H-pyrrolo[3,2-c]pyridin-2-yl]methanamine

(cyclobutylmethyl)[(6-{[1-(1H-indazol-4-yl)-1H-1,2,3-triazol-4-yl]methyl}-1H-indol-2-yl)methyl]amine

[(3,3-difluorocyclobutyl)methyl][(6-{[1-(1H-indazol-4-yl)-1H-1,2,3-triazol-4-yl]methyl}-1H-indol-2-yl)methyl]amine

(cyclobutylmethyl)[(6-{[1-(isoquinolin-4-yl)-1H-1,2,3-triazol-4-yl]methyl}-1H-indol-2-yl)methyl]amine

(cyclobutylmethyl)({6-[(1-{imidazo[1,5-a]pyridin-8-yl}-1H-1,2,3-triazol-4-yl)methyl]-1H-indol-2-yl}methyl)amine.

3-[1-({2-[({(Bicyclo[1.1.1]pent-1-yl)methyl}amino)methyl]-1H-indol-6-yl}methyl)-1H-1,2,3-triazol-4-yl]-5-methoxy-2-pyridinecarbonitrile;

3-[1-({2-[({(3-Fluorobicyclo[1.1.1]pent-1-yl)methyl}amino)methyl]-1H-indol-6-yl}methyl)-1H-1,2,3-triazol-4-yl]-5-methoxy-2-pyridinecarbonitrile;

5-Methoxy-3-[1-({2-[({(3-methylbicyclo[1.1.1]pent-1-yl)methyl}amino)methyl]-1H-indol-6-yl}methyl)-1H-1,2,3-triazol-4-yl]-2-pyridinecarbonitrile;

3-{1-[(2-{[(Cyclobutylmethyl)amino]methyl}-1H-indol-6-yl)methyl]-1H-1,2,3-triazol-4-yl}-5-methoxy-2-pyridinecarbonitrile;

3-{1-[(2-{(6-Aza-6-spiro[3.4]octyl)methyl}-1H-indol-6-yl)methyl]-1H-1,2,3-triazol-4-yl}-5-methoxy-2-pyridinecarbonitrile;

3-[1-({2-[(4,4-Dimethyl-1-piperidyl)methyl]-1H-indol-6-yl}methyl)-1H-1,2,3-triazol-4-yl]-5-methoxy-2-pyridinecarbonitrile;

N-((2-((6-azaspiro[3.4]octan-6-yl)methyl)-1H-pyrrolo[3,2-c]pyridin-6-yl)methyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxamide;

3-(1-((2-(((cyclobutylmethyl)amino)methyl)-1H-indol-6-yl)methyl)-1H-1,2,3-triazol-4-yl)-5-fluoropicolinonitrile;

1-cyclobutyl-N-((6-((4-(5-methoxypyridin-3-yl)-1H-1,2,3-triazol-1-yl)methyl)-1H-indol-2-yl)methyl)methanamine;

5-chloro-3-(1-((2-(((cyclobutylmethyl)amino)methyl)-1H-indol-6-yl)methyl)-1H-1,2,3-triazol-4-yl)picolinonitrile; and

2-((6-azaspiro[3.4]octan-6-yl)methyl)-6-((4-(imidazo[1,5-a]pyridin-8-yl)-1H-1,2,3-triazol-1-yl)methyl)-1H-pyrrolo[3,2-c]pyridine.

19~~21~~. A pharmaceutical composition comprising a compound according to any one of claims 1 to 18~~20~~, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

20~~22~~. A compound according to any one of claims 1 to 18~~20~~, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 19~~21~~, for use in:

(a) therapy;

(b) the treatment of a proliferative condition;

(c) the treatment of cancer;

(d) the treatment of leukaemia;

(e) the treatment of an autoimmune disease;

(f) the treatment of a neurological disease;

(g) the treatment of an inflammatory disease;

(h) the treatment of an infectious disease; or

(i) the treatment of a disease related to the re-activation of the silenced X-chromosome.

~~23. A compound according to any one of claims 1 to 20, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 21, for use in the treatment of a proliferative condition.~~

~~24. A compound according to any one of claims 1 to 20, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 21, for use in the treatment of cancer.~~

~~25. A compound according to any one of claims 1 to 20, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 21, for use in the treatment of leukaemia.~~

~~26. compound according to any one of claims 1 to 20, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 21, for use in the treatment of an autoimmune disease, a neurological disease, an inflammatory disease, an infectious disease or a disease related to the re-activation of the silenced X-chromosome.~~

21. Use of a compound according to any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 19, in the manufacture of a medicament for

(a) the treatment of a proliferative condition;

(b) the treatment of cancer;

(c) the treatment of leukaemia;

(d) the treatment of an autoimmune disease;

(e) the treatment of a neurological disease;

(f) the treatment of an inflammatory disease;

(g) the treatment of an infectious disease; or

(h) the treatment of a disease related to the re-activation of the silenced X-chromosome.